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ABSTRACT 
Mitogens, serum and growth factors, induce the secretion of several proteins in cell 
cultures. Mitogen regulated protein/proliferin (MRP/PLF) is one such protein secreted from 
3T3 cells 20 hours after the addition of fibroblast growth factor (FGF). 24p3/uterocalin is 
another protein induced 10 hours after FGF addition. When combined with cycloheximide, 
24p3/uterocalin secretion is increased by 5 fold. 
MRP/PLFs are glycoproteins, belonging to the prolactin-growth hormone family, 
expressed at high concentration during mid-gestation in the mouse placenta. MRP/PLFs are 
thought to stimulate angiogenesis in the placenta and the uterus, and stimulate uterine cell 
growth during mid-gestation. To further study the roles of these glycoproteins, recombinant 
MRP/PLFs were created, and expressed and purified in 293 human fetal kidney cells. 
To provide insights into the potential regulation of uterine cell proliferation by 
MRP/PLFs, the profiles of the wet weight and DNA content of the uterus were characterized 
and found to have a positive correlation with the expression profile of MRP/PLFs. Direct 
examination of MRP/PLF stimulation by estradiol-1?P or progesterone in day 8 and 9 
placental minced, organ cultures demonstrated no effect on secreted MRP/PLF levels. 
Purified MRP/PLFs were used to further study the uterine MRP/PLF receptor on primary 
uterine cell and organ cultures, and in an in vitro day 11 uterine membrane binding assay. No 
evidence of biological or binding activity to the uterine MRP/PLF receptor was detected. 
Expression of 24p3/uterocalin was detected in the embryonic spine on gestational day 
13 and shown to increase throughout gestation and over the life time of the mouse. In the 
vi 
liver 24p3/uterocalin mRNA levels were the highest in the late-gestational fetal liver and 
decreased within the first week after birth. The 24p3/uterocalin mRNA was also detected in 
the spleen of juvenile adults. The presence of 24p3/uterocalin mRNA in the fetal and juvenile 
liver and in the spine after birth appeared to correlate with hematopoiesis in these tissues and 
therefore it is hypothesized that 24p3/uterocalin may have a potential role in events related to 
both embryonic and adult hematopoiesis. 
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CHAPTER 1. 
GENERAL INTRODUCTION 
DISSERTATION ORGANIZATION: 
This dissertation contains five chapters. Chapter 1 is a literature review of mouse 
gestation accompanied by a description of the biochemical and functional properties of the 
prolactin-growth hormone family with an emphasis on one of its member; the growth factor 
regulated mitogen regulated protein/proliferin (MRP/PLF)- Chapter 2 describes the research 
accomplished to express and purify glycosylated recombinant MRP/PLFs from mammalian 
cells. Chapter 3 describes the characterization of the MRP/PLF receptors and a search to find 
novel roles for MRP/PLFs. Chapter 4 describes the characterization of another growth factor 
regulated protein called 24p3/uterocalin by showing its expression pattern in embryonic, 
juvenile and adult mouse. Chapter 5 contains a general discussion on the research findings as 
well as recommendations for future studies. Finally, an appendix is included to describe 
previous experiments aimed at developing tools to characterize MRP/PLFs interactions with 
known receptors. 
INTRODUCTION: 
During the course of evolution, mammals distinguished themselves from other animals 
by devising a new strategy for the development and the protection of their embryos. The 
embryos develop inside the uterus and physiological communication with the mother is 
established by the placenta. This temporary organ of embryonic origin connects the embryo to 
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the uterus and allows efficient exchange of nutrients and wastes between the mother and the 
embryo. Prior to the formation of the placenta, biochemical signals allow the first critical step 
of embryo development which is its implantation in the uterus. 
In mice, the gestational period is approximately 20 days beginning with fertilization of 
the oocyte at day 0 and implantation of the embryos (usually 10 to 12) at 4.5 days. By mid-
gestation, organogenesis of the embryo is virtually complete and the remaining half of the 
gestational period enables the embryo to quadruple in size. During mid-gestation there is a 
switch in the type of physiological communication occurring between the mother and the 
fetus. Prior to mid-gestation, most of the gas and nutrient exchanges have occurred through 
the yolk sac membrane. However, during the second half of gestation, the newly formed 
placenta becomes the critical organ in the biochemical communication between the mother 
and the growing fetus. The final stage in the relationship between the mother and the fetus 
involves the preparation for parturition (1). 
The prolactin-growth hormone (PRL-GH) family contains several placental proteins 
secreted by the placenta during gestation. The specific subfamily of mitogen regulated 
protein/proliferins (MRP/PLFs) are expressed during mid-gestation in the mouse. However, 
the role played by MRP/PLFs during this critical period in mouse development is not clear. 
Mid-gestation is the most critical period in mouse development because failure to establish 
proper communications with the uterus will result in rapid resorption of the embryo. 
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SUMMARY OF MOUSE GESTATION: 
Development of the fertilized egg to the preimplantation blastocyst 
After fertilization of the oocyte in the oviduct (day 0.5), the egg progressively starts 
DNA synthesis and cell division. Until the first cell division, the embryo relies primarily on 
the maternal proteins and RNAs accumulated during oogenesis (I). By the middle of the two 
cell stage (day 1.5), the embryonic genes are switched on (2) and degradation of most maternal 
RNAs and proteins increases (3,4). Until uterine implantation, development of the embryo 
does not seem to require exogenous growth factors as demonstrated by in vitro culture of 
embryos (5, 6). 
As the cells divide, the embryo will undergo three morphogenetic transitions prior to 
implantation (Figure 1). The first transition known as compaction begins at the eight-cell stage 
(day 2.5) when cells flatten and start forming tight junctions and gap junctions. The first 
embryonic "epithelium" is formed when the cells in contact with the uterine lumen evolve into 
the trophectoderm (TE). This "epithelium" encloses the first embryonic "endoderm" when the 
cells having no contact with the uterine lumen evolve into the inner cell mass (ICM) (7). 
The 32-cell (day 3) embryo undergoes the second morphogenetic transition called 
cavitation. During this process, the blastocoel, a cavity filled with liquid, is formed by the 
action of Na/K-ATPase pumps present on the basolateral membranes of the TE (8). At this 
stage, the TE begins to differentiate into the polar TE, cells in contact with the ICM, and the 
mural TE which encloses the blastocoel and does not contact the ICM (7). 
During the third morphogenetic transition, blastocoel expansion occurs with the 
continued activity of the Na/K-ATPase pumps. Expansion and contraction of the blastocyst, 
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together with enzymatic digestion, triggers its release from the zona pellucida (day 4). 
Arrangement of the blastocysts in the mouse uterus is determined by uterine contractions and 
the implantation of blastocysts will only occur if the uterus is primed by reproductive 
steroids (9). 
Fertilisation 
Oocyte 
Day 0.5 
Compaction 
8 Cell stage 
Dey 2.5 
Compacted 
embryo 
Future 
Endoderm 
Future 
TE 
Cavitation Z 
32 Cell stage 
Day 3 
ICM 
Blastocyst 
Polar TE 
Mural TE 
Blastocoel expansion 
Endoderm 
TE 
UE 
Dey 4.5 
Figure 1: Schematic of the m^jor changes during the development oi the fertilized egg. 
After fertilization the embryo undergoes compaction at the 8 cell stage. After further cell division the embryo 
undergoes cavitation when the blastocoel is formed. During cavitation, the cells keep on dividing and the 
embryo is now called a blastocyst After blastocoel expansion, the blastocyst implants to the uterine epithelium. 
TE: Trophectoderm, B: Blastocoel, ICM: Inner cell mass, UE: uterine epithelium. 
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Preparation of the uterus for implantation 
The uterus is prepared for implantation of the blastocysts by the action of ovarian 
estradiol and progesterone. This initial phase of the uterine preparation is independent of the 
presence of blastocysts in the uterine lumen (6). During ovulation (day 0.5) in the normal 
murine estrus cycle, estradiol-1?P is released by the ovaries and stimulates cell proliferation 
of the uterine luminal epithelium (10,11). Progesterone, secreted by the ovaries, normally 
rises and falls four days after ovulation, the length of a single estrus cycle. Mating will cause 
the extension of progesterone secretion to 9 days via bi-daily pituitary pulses of prolactin (12). 
Progesterone secretion initiates a switch in the luminal epithelial cells from the actively 
proliferating phenotype to a differentiated secretory phenotype (13) while simultaneously 
stimulating stromal cell proliferation (14). An "implantational pulse" of estrogen secreted by 
the ovaries (day 3) will then further stimulate growth of the uterine stromal cell population 
until the uterine lumen is forced to close around the blastocyst (1,10). 
Implantation of the blastocyst into the uterus 
Implantation requires the contact of the blastocysts with the uterine epithelium 
(day 4.5) followed by attachment and invasion of the blastocysts into the uterine stroma. The 
ability of the blastocysts to successfully contact the uterine epithelium is governed by the 
release of estrogen from the ovaries during the "implantational pulse" (15). This estrogen 
pulse stimulates apoptosis of the uterine luminal epithelial cells in contact with the mural TE. 
Death of the uterine epithelial cells, which are phagocytosed by the trophoblastic giant cells, 
allows the embryonic tissue to "invade" the endometrium (16,17) (Figure 2). Finally, 
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"invasion" of the embryo causes the uterus to respond by initiating decidualization (day 5.5), a 
process intrinsic to the uterus and required for implantation as described in the following 
section. 
Myometrium 
Figure 2: Schematic representation of a cross-sectioned gestational uterus at day 9. 
Once implanted the embryo is surrounded by several differentiated cell types: UE: uterine epithelium; PGC: 
primary trophoblastic giant cells; SGC: secondary trophoblastic giant cells: UC: uterine crypt; EMB: embryo. 
Transformation of the uterus after implantation 
Decidualization refers to the further increase in uterine size and weight after 
implantation of the blastocyst. The uterine stroma continues its rapid growth by cell 
multiplication, followed by differentiation, leukocytes infiltration (18,19) and edematous 
swelling of the uterine tissue due to a change in the vascular permeability (20). These changes 
ultimately lead to the formation of a new tissue: the decidua. However, the myometrium, 
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outer section of the uterus, is not modified and remains for the reconstruction of the uterine 
stroma and luminal epithelium after parturition (17). The uterus will be fully decidualized by 
day 14. However by day 9, the decidua in contact with the slowly growing embryo begins to 
undergo slow regression until day 14. From day 14 to parturition, the rate of regression 
increases dramatically to accommodate the rapidly growing embryo. The decidual regression 
continues until the embryo reaches the myometrium of the uterus (9, 21). 
The decidua is thought to play several roles in gestation. The newly decidualized 
uterine cells form a tight barrier around the embryo to protect it from the maternal immune 
system by restricting the passage of immunoglobulins, lymphocytes and even 
microorganisms (22). The decidua, in turn, protects the mother by moderating the 
"invasiveness" of the embryo by secreting several protease inhibitor, like TIMP-1, TIMP-3, 
for the proteases B/MMP9, uPA, secreted by the embryonic trophoblast (15). 
Formation of the placenta 
After implantation (day 5), the mural and polar trophectoderm will undergo different 
fates. The mural trophectoderm cells stop dividing and undergo enderoreplication, DNA 
replication without cell division, giving rise to the primary trophoblastic giant cells (23). The 
polar trophectoderm cells continue to proliferate and migrate in several directions. As the cells 
migrate away from the ICM they eventually stop dividing and differentiate into three major 
cell types. First, some polar TE cells migrate around the embryo and undergo 
enderoreplication of their DNA to replace some of the primary trophoblastic giant cells. 
Second, some TE cells migrate into the blastocoel cavity to ultimately become a part of the 
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umbilical cord. Third, some TE cells will migrate further in the endometrium and anchor the 
embryo in the uterus. This third TE cell population differentiates to form a part of the placenta 
and the TE cells in contact with the endometrium will evolve into secondary trophoblastic 
giant cells by enderoreplication of their DNA (1, 24). 
Transport of nutrients from the mother to the fetus occurs between day 9 and day 13 
through the "yolk sac" placenta. This primitive placenta is formed by the primary 
trophoblastic giant cells and cells originating from the embryo. The primary trophoblastic 
giant cells "invade" the decidua to come in contact with the maternal circulation and initiate 
the formation of blood sinuses. These trophoblastic giant cells enable nutrients, gas and waste 
to be exchanged between the mother and the embryo (15). 
At approximately day 10, exchanges of nutrient and waste between mother and embryo 
begin to shift from the "yolk sac placenta" to the true placenta. The bulk of the placenta is 
made from cells derived from the ICM and the polar trophectoderm. The available secondary 
trophoblastic giant cells will connect the embryo to the maternal circulation via blood sinuses 
(15). 
The placenta plays an important role in the maintenance of pregnancy (24). It allows 
the exchange of nutrients that are necessary for the successful development of the fetus. 
Through the placenta, the fetus communicates with the mother to keep the hormonal balance 
in a "pregnancy state" and to prepare the mother for lactation. In particular, the placenta 
synthesizes several members of the prolactin-growth hormone family which allows for the 
maintenance of gestation and preparation for lactation (25,26). 
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THE RODENT PROLACTIN-GROWTH HORMONE FAMILY: 
Interestingly, although the prolactin-growth hormone family constitutes part of the 
major proteins secreted from the mouse placenta and the decidua during gestation, the first 
two members of this family, prolactin (PRL) and growth hormone (GH) were initially cloned 
from murine anterior pituitary gland (27). In the mouse, prolactin is released from the anterior 
pituitary throughout gestation to induce the corpus luteum's secretion of progesterone to 
maintain pregnancy (luteotropic action). However, it was shown that when the anterior 
pituitary is removed after mid-gestation, pregnancy can be maintained without prolactin 
suggesting another source for a PRL-like activity. This activity was identified in placental 
extracts (28). Subsequently, isolation of the proteins which had this PRL-like activity and 
subsequent cloning of their cDNAs identified placental lactogen I and H, PL-I and PL U 
respectively, as members of the PRL-GH family (29, 30). Several additional members were 
discovered by finding sequence homologies in Expressed Sequence Tag databases (31-38). To 
date, over 20 members comprising the PRL-GH family have been characterized. 
A common feature for this family of proteins lies in their tissue specific expression 
patterns. All family members, except for PRL and GH, which are secreted by the anterior 
pituitary, are produced during gestation by the placenta or the decidua. The trophoblastic giant 
cells of the placenta are known to express all the currently characterized members of the PRL-
GH family (25). 
A second feature is a common exon/intron structure suggesting that all the members of 
the mouse PRL-GH family arose from gene duplication of prolactin and are all located on 
chromosome 13. The typical gene structure is defined by five exons and four introns. 
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However, members of one subfamily, the prolactin like protein-C (PLP-C), have an additional 
small exon coding for an aromatic amino acid rich region between exons two and three. The 
significance of this extra intron is still unknown but it is believed to modulate the PLP-C 
receptor binding activities in vivo (33, 36, 38, 39). 
A third common characteristic of PRL-GH family members lies within the conserved 
features of their protein primary structure. All family members are secreted proteins of 
approximately 200 amino acids and can be classified according to the number of conserved 
cysteines. Each individual member contains at least four conserved cysteines (three of them 
located at the C-terminus) which are involved in the formation of intramolecular disulfide 
bridges. Some family members contain an additional cysteine in the middle of the protein or 
two additional cysteines at the N-terminus. With the exception of PL-II, all family members 
are post-translationally modified by the addition of carbohydrates. The structure and extent of 
the glycosylation depends on the time during gestation and cell type expressing these proteins. 
The variation in glycosylation add a new level of regulation for the action of PRL-GH family 
members (25). For example, the degree of glycosylation of PRL affects the activity of human 
pituitary prolactin in the pigeon crop assay (40) and rat lymphoma Nb2 cell based prolactin 
receptor binding assay (41). 
Despite their common features, there has been great difficulty in defining all the 
biological functions and receptors for the PRL-GH family members. The "classical members" 
such as PRL, GH, PL-I and PL-II are the best characterized and bind to the PRL receptor to 
play roles in gestation as mammotrophic, stimulation of mammary gland development, and 
luteotropic hormones. These same PRL-GH family members also play over 300 different roles 
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in cell proliferation and differentiation, osmoregulation, metabolism, behavior, reproduction 
and maintenance of optimum immune protection at the cellular level (42). The cellular and 
molecular mechanisms of these roles were better characterized using mouse PRL receptor 
knock-outs (43). The biological functions and receptors for the "non-classical" members are 
gradually being defined. One of the best characterized PRL-GH "non-classical" subgroups is 
the family of mitogen regulated protein/proliferin (MRP/PLFs). 
CHARACTERIZATION OF MRP/PLFS AND THEIR RECEPTORS: 
Discovery of MRP/PLF and their gene structure 
Mitogen regulated proteins (MRPs) are 34 kDa proteins and were first discovered as a 
family of glycoproteins secreted by mice Swiss 3T3 cells and Balb/c normal liver cells (BN/L) 
stimulated by epidermal growth factor (EGF) and fibroblast growth factor (FGF) (44). 
Proliferin (PLF) was originally identified, by differential screening of a cDNA library, as a 
422 bp mRNA transcript upregulated in response to serum stimulation of quiescent Balb/c 
3T3 cells (45). The deduced amino acid sequence from the mRNA revealed that PLF belonged 
to the prolactin/growth hormone family (46). Cloning of the MRP cDNA from 
BN/L cells showed that MRP was identical to PLF (47). 
Further characterization of mrp/plf by Southern blot analysis suggested that there are at 
least four to five copies of the mrp/plf gene present in the mouse genome (48). There are four 
characterized mrp/plfs: plfl (46), plf2 (49), mrp3 (50) and mrp4 (51). Plfl, plf2, mrp3 are 
99 % identical at the cDNA level, differing by only three base pairs. However, mrp4 (cloned 
from day 13 placental RNA) is 97 % identical to plfl (51). 
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MRP3, the only member of the MRP/PLF family with a known gene structure, 
possesses the characteristic five exons/four introns structure of the prolactin/growth hormone 
family members (25,50). MRP/PLFs have been mapped to chromosome 13 (39). The 
deduced amino acid sequences show three N-glycosylation consensus sequences for PLF1, 
PLF2 and MRP3, and only one for MRP4 due to base pair changes (Figure 3). During mid-
MPRL 1 mnsqgsaqka. gtlllllisn llfcqnvqpL PICS A--GDC QTSLRELFDR WTLSHYIHT 
PLF1 1 mlpsliqpcs willlllvns sllwknva& PMCAMRNGFC FMSFEDTFEL AGSLSHNISI 
PLF2 1 mlpssiqpcs willlllvns sllwknvasF PMCAMRNGBC FMSFEDTFEL AGSLSHNISI 
MRP3 1 mlpssiqpcs willlllvns sllwknva& PMCAMRNGBC FMSFEDTFEL AGSLSHNISI 
MRP4 1 mlpsliqpcs willlllvns sllwknvasL PMCAMRNDRC FMFFEOTFEL AGSLSHNISI 
A A A A  A A A A A  A  A  A A A A A  A A A  A A A A A A A A A  A A  j  A A A  A  A  |  A  A  A  A  A A A  A  A  A A A A A A A A A A  
*  * *  *  *  *  |  *  *  *  * * *  *  * *  *  * «  
mPRL 61 LYTDMFIEFD KQYVQDREFM VKVTNDCPTS SLATPEDKEQ ALKVPPEVLL NLILSLVQSS 
PLF1 61 EVSELFTEFE KHY3JV9GLR DKSPMRCNTS FLPTPENKEQ ARLTHYSALL KSGAMILDAW 
PLF2 61 EVSELENEFE KHYSNV3GLR DKSPMFOJTS FLPTPENKEQ ARLTKYAALL KSGAMISDAW 
MRP3 61 EVSELENEFE KHY3\TV9SLR DKSPMRCNTS FLPTPENKEQ ARLTHYAALL KSGAMILDAW 
MRP4 61 EVSELFTEFE KHYSNVPGLR DKSPMRCHTS FLPTPENKEQ ARHIRYEALL KSGDMILDAW 
mPRL 121 SDPLFQLITG VGGIQEAPEY ILSRAKEIEE QNKQLLEGVE KIISQAYPEA KGNGIYFVWS 
PLF1 121 ESPLDDLVSE LSTTKNVPDI IISKATDIKK KINAVRNGVN ALMSTMLQNG DEEKKNPAW-
PLF2 121 ESPLDDLVSE LSTTKNVPDI IISKATDIKK KINAVRNGVN ALMSTMLQNG DEEKKNPAW-
MRP3 121 ESPLDDLVSE LSTTKNVPDI IISKATDIKK KINAVRNGVN ALMSTMLQNG DEEKKNPAW-
MRP4 121 ENPLDYLVSE LSTTKNVPDI IISKATDIKK KINAVQNGVN ALMSTM--NG DEENKNPAW-
mPRL 181 QLPSLQGVDE ESKILSLRNT IRCLRRDSHK VDNFLKVLRC QIAHQNNC 
PLF1 181 FLQSDNE DARIHSLYCM ISCLDNDFKK VDIYLNVLKC YMLKIDNC 
PLF2 181 FLQSDNE DARIHSLYGM ISCLDNDFKK VDIYLNVLKC YMLKIDNC 
MRP3 181 FLQSDNE DARIHSLYGM ISCLDNDFKK VDIYLNVLKC YMLKIDNC 
MRP4 181 FLQSDNE DARIRSSYGM ISCLDNDFKK VDIYLNILKC YMLKIDNC 
—I | 
Figure 3: Amino add alignment for MRP/PLFs and moose prolactin. 
The amino acid sequences deduced from the cDNA for mouse prolactin (mPRL) and MRP/PLF (PLF1, PLF2. 
MRP3. MRP4) were aligned according to the position of the 6 conserved cysteines (indicated by the I above and 
underneath the sequences). The amino acids of the secreted proteins are in capital letters and the amino acid from 
the signal sequences are in lower case and italicized. The putative recognition sequences for N-glycosylation 
(NXS motif) are underlined within the sequences. The conserved amino acids for mPRL and all 4 MRP/PLFs are 
represented by the * above the sequences. The conserved amino acids within the MRP/PLF family are 
represented by the A underneath the sequences. 
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gestation mrp/plf mRNAs and proteins were detected by in situ hybridization and 
immunohistochemistry in trophoblastic giant cells (52). These characteristics confirmed that 
MRP/PLFs were true members of the prolactin/growth hormone family. 
Receptors for MRP/PLFs 
Recombinant PLF1 expressed and purified from CHO (Chinese hamster ovary) cells 
was shown to bind to the IGFII/mannose-6-phosphate /cation independent (IGFII/M6P) 
receptor from the mouse placenta and the liver of both fetuses and pregnant mice. The 
maximal binding activity was observed in day 16 maternal and fetal liver membranes. Placental 
membrane binding was shown to increase from the formation of the placenta (day 10 of 
gestation) throughout the end of pregnancy (day 19 to 20) (53). 
Another, as yet to be identified, receptor was later characterized in day 11 uterine 
membranes. MRP/PLFs isolated from the conditioned medium of FGF stimulated BN/L cells 
were shown to bind to uterine membranes with the maximal binding activity observed in 
day 11 uterine membranes. Excess cold mannose-6-phosphate was used in competitive 
binding experiments to establish that the characterized binding activity was not to the 
IGFH/M6P receptor but rather to the putative uterine receptor. Furthermore, PRL, PL-I or 
GH do not compete with MRP/PLFs for binding to the uterine membranes suggesting that the 
characterized receptor is not the PRL receptor (54). These results supported the observation 
that recombinant PLF1 did not bind to the prolactin or growth-hormone receptors (53) and 
led to the recognition ofMRP/PLFs as "non-classical" members of the PRL/GH family (25). 
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Detection of MRP/PLFs binding in vivo 
By radioimmunoassay, MRP/PLFs were found to be secreted into the maternal blood 
stream and the amniotic fluid with a peak of expression during mid-gestation (52).1 "^Iodine-
labeled PLF1 bound to embryonic heart and blood vessels in the area of the dorsal artery 
between days 10 and 18 of gestation. Also, at the same days of gestation, 
immunohistochemistry studies detected MRP/PLFs in the endothelial cell lining of blood 
vessels of the developing vertebrae and ribs of the embryo (55). 
Interestingly, temporal expression patterns during gestation differ between MRP/PLF 
family members within the placenta. The profile of expression of the different mrp/plf s in the 
placenta was established by RT-PCR followed by specific restriction enzyme digestion which 
allowed for a differentiation between all the known mrp/plf s at the DNA level. These profiles 
showed that mrp3 constituted the majority of the mrp/plfs present in the placenta. Plfl was 
also present to a lesser extent and matched the profile of mrp3 expression. However, mrp4 
was expressed later during gestation with a peak at day 12 compared to a peak at day 10 for 
mrp3 and plfl- A smaller 27 kDa form of MRP/PLF can be detected by Western blot in 
addition to the 34 kDa form. The secretion of the 27 kDa protein during gestation matches the 
profile of expression of the mrp4 mRNA. (56). 
MRP/PLFs were the first members of the PRL-GH family aside from PRL and GH 
that are found to be expressed in both male and female adult mice beyond gestation. For 
instance, mrp4 mRNA was detected in the adult tail and ear by RT-PCR. 
Immunohistochemical studies localized the expression of MRP4 to the keratinocytes of the 
outer root sheath of the tail hair follicles (51). MRP3 was detected in the adult mouse during 
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wound healing in keratinocytes near the wound edge. In primary newborn keratinocyte cell 
cultures, mrp3 mRNA is upregulated by keratinocyte growth factor. During hair follicle 
morphogenesis, MRP3 is expressed in the outer root sheath during mid-anagen with the 
highest expression in late-anagen which might suggest a role for MRP3 in hair follicle 
cycling (57). 
Physiological functions of MRP/PLFs 
The binding of recombinant PLF1 to the endothelial cell lining of blood vessels 
suggested a possible role in angiogenesis. Recombinant PLF1 was shown to induce the 
migration of bovine capillary endothelial cells, and stimulate neovascularization in the rat 
cornea assay (58). The addition of mannose-6-phosphate inhibited the angiogenic activity of 
PLF1 in the endothelial cell migration assay suggesting that the IGFH/M6P receptor was 
required for this activity (59). Further characterizing of the angiogenic activity showed that 
PLF1 can induce endothelial cell migration through a G-protein coupled MAPK-dependent 
pathway (60). 
Also, in the GATA 2 and 3 transcription factor knockouts, MRP/PLFs protein and 
mRNA are down-regulated in the placenta which correlate with the decrease in blood vessel 
formation in the placenta and the uterus. The mrp/plf promoters were shown to contain the 
GATA 2 and GATA 3 consensus binding sites for the GATA transcription factors. Therefore 
it has been hypothesized that expression of MRP/PLFs in the placenta during mid-gestation is 
regulated by GATA 2 and GATA 3 and that MRP/PLFs are involved in the formation of 
blood vessels in the decidua (61). Furthermore, MRP/PLFs stimulate thymidine incorporation 
16 
in mid-gestational primary uterine cell cultures suggesting a role for MRP/PLF in uterine cell 
proliferation (54). 
These results suggest that MRP/PLFs have angiogenic activity and also may be growth 
factors involved in the decidualization of the uterus during mid-gestation. The presence of 
MRP/PLFs binding in the fetal heart, ribs and liver is still unclear, but it could involve 
angiogenesis, or growth of certain embryonic tissues (15, 55). MRP/PLFs expression in the 
hair follicle and wound healing could also suggest similar roles in keratinocyte migration and 
cell proliferation for MRP/PLFs in the epidermis of the skin (57). 
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CHAPTER 2. 
EXPRESSION AND PURIFICATION OF RECOMBINANT MRP/PLFS 
USING 293 HUMAN FETAL KIDNEY CELLS 
ABSTRACT: 
MRP/PLFs are glycoproteins, belonging to the prolactin-growth hormone family, with 
an average molecular weight of 34 kDa for PLF1, PLF2, MRP3 and 27 kDa for MRP4. They 
were originally found to be secreted by trophoblastic giant cells of the mouse placenta during 
mid-gestation. MRP/PLFs are thought to stimulate angiogenesis in the placenta and the uterus 
and stimulate uterine growth during mid-gestation. Also, MRP3 is expressed during wound 
healing and normal hair follicle development. To further study the role of these glycoproteins, 
a purification method was developed. The 5' end of all the known mature mrp/plf cDNAs were 
PCR-modified to add three features to facilitate expression and purification: the human 
placental alkaline phosphatase signal sequence, a histidine tag, and an enterokinase 
recognition site. The modified cDNAs were stably transfected in 293 human fetal kidney cells 
and the histidine tagged MRP/PLFs accumulated in the conditioned medium. His-MRP/PLFs 
were separated from contaminating proteins using nickel-chelate then pea-lectin affinity 
chromatography. His-PLFl and His-MRP3 were successfully expressed and purified, whereas 
His-MRP4 did not accumulate in the conditioned medium of stably transfected 293 cells or 
transiently transfected COS cells. Using enterokinase, the histidine tag was successfully 
removed from His-MRP3 to release the mature glycosylated form of the MRP3 protein. 
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INTRODUCTION: 
The number of genes in the MRP/PLF family has been estimated at six (1), and four 
have been cloned and characterized: PLF1 (2), PLF2 (3), MRP3 (4), and MRP4 (5). The 
protein primary structure deduced from cDNAs suggested that MRP/PLFs are ^-glycosylated 
proteins and are members of the expanding prolactin-growth hormone family (2,6). 
Unglycosylated MRP/PLFs have a molecular weight of 22 kDa (7). PLF1, PLF2, MRP3 are 
secreted glycoproteins with an average apparent molecular weight of 34 kDa. MRP4 is also a 
secreted glycoprotein but it lacks two of the N-glycosylation consensus sequences of the 
known MRP/PLFs. MRP4 has an average molecular weight of 27 kDa which is consistent 
with its lesser degree of glycosylation compared to other MRP/PLF family members (5). 
PLF1 was shown to stimulate angiogenesis through the insulin-like growth factor W 
mannose-6-phosphate receptor (IGFD/M6P receptor). This binding relies upon the presence of 
mannose-6-phosphate in the carbohydrate moieties of these glycoproteins (8). During mid-
gestation in the mouse, a MRP/PLF binding activity different from the IGFD/M6P receptor 
was characterized in the uterus and suggested a role in uterine cell proliferation (9). More 
recently, the role of MRP/PLFs was broadened by the discovery of MRP3 expression during 
wound healing and normal hair follicle development (10). 
To further study the roles of these proteins, each of the different glycosylated 
MRP/PLFs needed to be purified in milligram quantities. Initially, Swiss 3T3 cells were 
stimulated with fibroblast growth factor (FGF), and the clarified conditioned medium was 
subjected to gel filtration (Biogel P-200) followed by pea-lectin affinity chromatography (11). 
However, the yield was low, and even though the main MRP/PLF mRNA expressed by FGF-
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stimulated 3T3 cells was mainly plfl, mrp3 mRNA was also detected by RT-PCR followed by 
specific restriction digestion to differentiate between the different MRP/PLF cDNAs (5, 10). 
To obtain purified PLF1 and MRP3, a baculovirus expression system using insect cells 
was developed. However, in insect cells, PLF1 and MRP3 were glycosylated differently 
compared to placental MRP/PLFs. Such differences could potentially lead to differences in 
binding to the uterine receptor. Secondly, the eluate from the final purification step contained 
a contaminant that co-eluted with the recombinant PLF1 and MRP3 as shown by comparing 
silver stained polyacrylamide gels and Western blots. For both reasons, the baculovirus system 
for MRP/PLF expression was no longer used (Shogren, Bendickson, and Nilsen-Hamilton, 
unpublished results). 
The purification strategy described here, uses the 293 human fetal kidney cell line (293 
cells) as a host for the secretion of recombinant MRP/PLFs. These cells were chosen for 
several reasons. First, they can be easily transfected; second, they can be adapted to cell 
suspension; and third, compared to insect cells, these mammalian cells have the ability to 
glycosylate proteins with a pattern consistent with the endogenous proteins. 
All known MPR/PLF recombinant cDNAs were successfully engineered to have a 
secretion signal sequence, a histidine tag and an enterokinase cleavage site. Stable clones of 
293 cells expressing PLF1, PLF2 and MRP3 were generated and a purification scheme was 
established to purify His-PLFl and His-MRP3 using nickel chelation and pea-lectin affinity 
chromatography. 
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MATERIALS AND METHODS: 
Plasmid construction 
Plasmids used to transfert 293 cells, with the modified cDNAs for PLF1, PLF2, MRP3 
and MRP4 (Figure 1), were obtained by PGR amplification of different plasmids containing 
Figure 1: Structure of the nucleic acid cassette used for stable transfections of 293 cells. 
CMV represents the cytomegalovirus promoter. Signal sequence represents the 66 bp of the human placental 
alkaline phosphatase signal sequence. His represents the sequence for the histidine tag coding for 6 histidines 
(CAT),. EK represents the recognition sequence for the enterokinase coding for the amino acid DDDDK. 
MRP/PLF represents the cDNA coding for the mature secreted form of PLF1, PLF2, MRP3, or MRP4. 
the cDNAs of MRP/PLFs (PLF1: pRSVPLFl, PLF2: pcDNAPLF2, MRP3: 
MRP3/ID/5DS39, MRP4: MRP4/pcDNA3). The 5' end primer Rsal-EK-PLFl contained a 
Rsal restriction site and the coding sequence for the enterokinase recognition sequence 
followed by the first 21 nucleotides coding for the first 7 amino acids of the secreted form of 
PLF1, PLF2 and MRP3. The 5' end primer RsaI-EK-MRP4 was similar to Rsal-EK-PLFl 
except it annealed to the cDNA of the secreted form of MRP4. The 3' end primer 
ZMrpHindm placed HindHl site into the 3' untranslated region of each MRP/PLFs (Table I). 
Table I: Sequences of primers used for plasmid construction 
Primer Sequence 
Rsal-EK-PLFl: 5 • GGGGTAOCATGACGATGACGATAAGTTTCCCATQTQTQCAATGAGQ 3' 
RsaI-EK-MRP4: 5 ' GGG G TACCATGACGATGACGATAAGTTGCCCATQTGTGCAATQAGG 3 ' 
ZMrpHindm: 5 ' GAAAAGCTTQTCAACAACAAATTCAAAAG 3' 
MRP/PLF 
Italics represent restriction sites. Underlined is the enterokinase recognition sequence. In bold is the sequence 
from the MRP/PLFs' genes. 
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The PGR reactions were performed using the Expand High Fidelity PGR system 
(Roche) in a Perkin-Elmer GeneAmp 2400 thermocycler. The amplification program was a 
denaturation step at 94 °C for 3 min, followed by 30 cycles of amplification (94 °C for 30 s, 
60 °C for 30 s, 72 °C for 50 s), and a final elongation step at 72 °C for 5 min. 
The expected 686 bp products were gel-purified using the QIAEXII gel extraction kit 
(Qiagen) and digested with Rsal and HirufiXL Restriction digests with Xbal and Rsal of 
plasmid pcDNAPLFl(His,EK2)PLl 17 gave a 187 bp fragment containing the human 
placental alkaline phosphatase signal sequence followed by a histidine tag. The plasmid 
pcDNA3.1(-) (Invitrogen Life Technologies) was also digested with Xbal and Hindlll. After 
the restriction digests, the digested plasmid pcDNA3.1(-), the 686 bp and the 187 bp 
fragments were gel purified, ligated together and electroporated in the XL 1-blue bacterial 
strain (Stratagene). The plasmids were isolated and sequenced (DNA Synthesis and 
Sequencing Facility, ISU). The plasmids containing the modified sequences of PLF1, PLF2, 
MRP3, and MRP4 were called pcDNA(His,EK)PLFl, pcDNA(His,EK)PLF2, 
pcDNA(His,EK)MRP3 and pcDNA(His,EK)MRP4, respectively. 
Cell culture and transections 
COS cells were grown in DMEM high glucose (Gibco Invitrogen Corporation) 
supplemented with 10 % calf serum (Summit) and 10 U/ml Penicillin/Streptomycin (Gibco 
Invitrogen Corporation), at 37 °C in a 10 % CO, humidified atmosphere. 
COS cells grown in 3 cm tissue culture dishes (Sarstedt) to 50 % confluency were 
transiently transfected using the DEAE-Dextran method (5). Secreted proteins accumulated in 
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the medium for 5 to 8 days and the presence of MPR/PLFs was assessed by Western blot. 
293 cells were grown in DMEM high glucose supplemented with 5 % calf serum and 
10 U/ml Penicillin/Streptomycin. Tissue culture dishes used for 293 cells were treated for 
30 min at room temperature before plating with 0.1% Type A gelatin (porcine skin, Sigma) to 
help the attachment and even spreading of the cells. The cells were grown at 37 °C in a 10 % 
CO, humidified atmosphere. Stable transfections were obtained in 293 cells plated and grown 
to 50 % confluency in 3 cm tissue culture dishes. Following the manufacturer's instructions, 
0.1 |lg of each plasmid were transfected using 0.3 % v/v Lipofectamine™ (Gibco Invitrogen 
Corporation) in DMEM high glucose for 6 h. The cells recovered overnight and the 
transaction medium was replaced with fresh growth medium. After 48 h the cells were 
transferred, using 0.025% trypsin, to a 10 cm tissue culture dish for selection in growth 
medium containing 300 llg/ml G418 (Sigma). After selection for 14 days, the cells were 
detached using 0.025 % trypsin and diluted to 15 cells/ml followed by the plating of 0.1 ml in 
individual wells of a 96 well plate. The cells were grown 3 to 4 weeks and the conditioned 
medium was collected when it started to acidify (indicated by the phenol red). The cells 
(estimated to be 20 to 90 % confluent) were detached using trypsin and cryopreserved at 
- 80 °C. The conditioned medium was analyzed for the presence of the different MRP/PLFs by 
Western blot. 
Point mutation in MRP4 cDNA 
Sequencing of pcDNA(His,EK)MRP4 showed that the cloned MRP4 cDNA contained 
a point mutation at position 155, from the translational start of MRP4 when compared to the 
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native placental MRP4 cDNA. To obtain the native form of MRP4 in pcDNA3.1(-), this 
cloned cDNA had to be point-mutated to replace the point mutated adenine at position 155 
with a guanine correction. The QuickChange™ method (Stratagene) was used with the 
following primers. Primer 1: G AC AC ATTT GAATT AGCCGGC AGTTT GT CTC. Primer 2: 
GAGACAAACTGCCGGCTAATTCAAATGTGTC. Plasmids containing the mutation were 
generated with the following PGR program 1 min at 95 °C, 12 cycles (95 °C 1 min, 55 °C 
1 min, 68 °C 13 min), 2 min at 37 °C using the Perkin-Elmer Gene Amp 2400 thermocycler. 
The mutated cassette containing the signal sequence, the histidine tag and the succesfiilly 
mutated cDNA was cut out using Xbal and HindUl and recloned into the pcDNA3.1(-) vector 
and confirmed by sequence analysis (DNA Synthesis and Sequencing Facility, ISU). 
SDS polyacrylamide gel electrophoresis 
Samples to be separated by SDS PAGE were loaded on a 12.5% acrylamide gel and 
electrophoresis was completed at 35 mA for 3 h in 0.4 M Glycine, 50 mM Tris, 1 % SDS 
pH 8.35. The molecular weight markers were bovine serum albumin (66 kDa), ovalbumin 
(45 kDa), carbonic anhydrase (30 kDa), myoglobin (18 kDa), cytochrome c (12.5 kDa). 
Western blot analysis and densitometry 
MRP/PLF containing samples were first resolved by SDS-PAGE. The proteins were 
transferred on nitrocellulose membrane (Nitrobind 0.45 Jim, Osmonics) using a Hoefer TE50 
apparatus at 30 V for 12 h at 4 °C. The membrane was stained with 0.2 % Ponceau S in 
3 % trichloroacetic acid to ascertain uniform transfer of proteins to the membrane. After 
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destaining with water, the membrane was incubated for 30 min at 37 °C in blocking solution 
(5 % wt/vol nonfat milk in 0.14 M NaCl, 5 mM KC1,0.7 mM Na^HPO*, 25 mM Tris, 
0.02 % wt/vol sodium azide, pH 7.5). The blocking solution was removed and replaced with 
fresh blocking solution containing rabbit antiserum 89Rbl3b raised against MRP/PLF purified 
from 3T3 cells at a final dilution of 1/200. This antiserum is immunoreactive to PLFl, PLF2, 
MRP3 and MRP4. After incubation at room temperature for 90 min, the membrane was 
washed three times (10 min each) in wash buffer (140 mM NaCl, 2.7 mM KC1, 1.5 mM 
KH2P04, 8 mM Na^HPO*, pH 7.5). The first wash contained 1 % Tween 20. The membrane 
was then incubated for 30 min at room temperature with 8 ng/ml of goat IgG anti-rabbit 
conjugated to peroxidase (Pierce) in wash buffer. The membrane was washed three times 
(10 min each) in wash buffer, with the first wash containing 1% Tween 20. The presence of 
peroxidase activity was detected by enhanced-chemiluminescence using ECL™, (Amersham 
Pharmacia) and exposure of X-ray film (Kodak). 
The intensity of the exposed bands on the X-ray film was determined using a scanning 
densitometer (Biomed Instruments) measuring directly off the exposed X-ray films. 
Silver stain 
The different affinity chromatography fractions were resolved by SDS-PAGE, stained 
in 0.5 % Coomassie blue R-250,0.25 % isopropanol, 0.1 % glacial acetic acid and destained 
with 0.1 % isopropanol, 0.1 % glacial acetic acid. Unless indicated otherwise, the following 
steps were performed at room temperature for 30 min. For enhanced protein staining by silver 
staining (12), the gel was prefixed in prefix A (50 % methanol, 10 % acetic acid) then in 
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prefix B (5 % methanol, 7 % acetic acid) followed by fixing in 10 % glutaraldehyde. After 
thorough rinsing with deionized water for at least one hour with 5 to 6 water changes, the gel 
was reduced with 5 |lg/ml dithiothreitol in water, followed by impregnation with 0.1 % silver 
nitrate. The silver stain was developed using 0.02 % formaldehyde in 3 % sodium carbonate. 
Development was stopped after 10 to 15 min by adding directly to the developer 2.3 M citric 
acid to a 0.1 M final concentration with a pH of 7. 
Production of conditioned medium containing His-MRP/PLFs 
Roller bottles used for 293 cells were treated, before plating, for 1 h at room 
temperature with approximately 1 rotation per minute at 37 °C with 0.1% Type A gelatin 
(porcine skin, Sigma) to help the attachment and even spreading of the cells. The stably 
transformed 293 cells expressing the different recombinant MRP/PLFs from two confluent 
15 cm tissue culture dishes were «suspended in 400 ml of growth medium and seeded in one 
gelatin treated 1700 cm2 pleated roller bottle (Corning Science Products), C02 was added to 
the bottle to adjust the pH to approximately 7.3 before the bottle was sealed. The roller bottle 
was rotated at approximately 1 rotation per minute at 37 °C. When the cells were confluent 
(after 2 to 4 days), the medium was removed and the cells were washed with 100 ml warm 
TBS (140 mM NaCl, 8 mM NajHPO,, 2.7 mM KC1, 1.5 mM KH2PQ4,0.68 mM CaCl2, 
0.5 mM MgClj. pH 7.5 ) by rotating the bottle briefly. After removing the TBS, 400 ml of 
serum free medium was added to the cells, C02 was again added, the bottle was sealed and 
the cells were incubated and rotated as above. After 7 to 8 days the medium was collected and 
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cell debris was removed by centrifiigation at 10,000 x g for 30 min at 4 °C. This provided 
clarified conditioned medium containing recombinant histidine tagged MRP/PLFs. 
His-MRP/PLFs purification protocol 
The clarified conditioned medium from stably transfected 293 cells was concentrated 
10 fold by ultrafiltration through a YM10 membrane (Millipore) using N2 at 30 PSI at room 
temperature. A buffer exchange step was done by adding buffer A (50 mM sodium phosphate, 
300 mM NaCl, pH 8.0) to reconstitute the original volume. Ultrafiltration was resumed until 
the conditioned medium was concentrated to 1/20 of its original volume. 
The concentrated conditioned medium was further clarified by centrifiigation for 
30 min at 10,000 x g at 4 °C. Nickel chelate resin (Ni-NTA slurry, Qiagen) was equilibrated in 
wash buffer A and 1 ml of resin was added to every 20 ml of clarified concentrate. The 
mixture was rocked overnight at 4 °C to allow binding to the resin. The resin was supported in 
a poly-prep chromatography column (Biorad), the concentrate was passed through the packed 
resin and the unbound fraction was collected. The resin was washed with buffer A , followed 
by buffer B (50 mM sodium phosphate, 300 mM NaCl, pH 6.0). The volume of the these 
washes was equal to the volume of the unbound fraction. The bound proteins were eluted by 
sequentially adding 2 ml of a 50 mM sodium phosphate, 300 mM NaCl pH step gradient at 
pH 6.0, pH 5.5, pH 5.0, pH 4.5, and finally pH 4.0. Bound His-MRP/PLFs was eluted upon 
addition of pH 4.5 buffer. 
The fractions containing His-MRP/PLFs, detected by Western blot, were pooled and 
loaded on a pea-lectin column equilibrated in buffer C (10 mM Tris, 0.5 M NaCl, pH 8.0). 
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The column was washed with 10 column volumes of buffer C. Before stopping the flow, 
1 column volume of buffer C containing 0.2 M of methyl-a-D-mannopyranoside was added to 
the column and left at 4 °C overnight The flow was resumed and 2 ml fractions were 
collected. 
From the pea-lectin column the fractions containing His-MRP/PLFs (detected by 
Western blot) were pooled and mixed with 5 ml of fresh Ni-NT A resin equilibrated in buffer 
A and rocked overnight at 4 °C to allow binding. The resin was supported in a poly-prep 
chromatography column (Biorad), the concentrate was passed through the packed resin and 
the unbound fraction was collected. The resin was washed with buffer A, followed by 
buffer B. The volume of the washes was equal to the volume of the unbound fraction. The 
bound proteins were eluted by sequentially adding 2 ml of a 50 mM sodium phosphate, 
300 mM NaCl pH step gradient at pH 6.0, pH 5.5, pH 5.0, pH 4.5, and finally pH 4.0. Bound 
His-MRP/PLFs was eluted upon addition of pH 4.5 buffer. 
At each step, recombinant MRP/PLFs were detected by Western blot and the relative 
amounts in each fraction were determined by densitometry. Protein contaminants were 
detected by silver staining. The amount of total protein in the fractions was estimated by using 
the Coomassie Plus protein assay reagent (Pierce). 
Enterokinase cleavage of the purified proteins 
The fractions containing purified His-MRP/PLFs were pooled, dialyzed against 50 mM 
ammonium bicarbonate, pH 8.0 at 4 °C and lyophilized. The histidine tagged MRP/PLFs were 
resuspended in 10 mM Tris-HCl pH 7.5. The histidine tag was cut and removed using 1 unit 
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of recombinant enterokinase (Novagen) for 20 |ig of His-MRP/PLF according to the 
manufacturer's recommendation. Typical incubations were carried out for 48 to 72 h. To 
separate the histidine-tag free from the histidine-tagged proteins, Ni-NTA resin was added to 
the reaction mixture and rocked at room temperature for 1 h. The cut recombinant MRP/PLFs 
were separated from the nickel column using a spin basket provided with the kit. 
RESULTS: 
Generation of stable clones expressing recombinant proteins 
Protein sequencing of recombinant PLFl purified from the medium of transfected 
CHO cells showed that phenylalanine 30 was the first amino acid of secreted PLFl (13). To 
facilitate the purification of mature MRP/PLF proteins from transfected 293 cells the cDNAs 
of these proteins were modified at the 5' end to encode the mrp/pifs cDNA for the mature 
proteins. In addition the 5' end was sequentially modified to add the strong signal sequence of 
the human placental alkaline phosphatase (hpAP), a six-histidine tag and an enterokinase 
recognition site by PCR. The enterokinase sensitive site was added to allow cleavage of the 
histidine tag to release only the mature secreted form of MRP/PLFs. The cytomegalovirus 
promoter was used to increase transcription of the expression cassette (Figure 1). 
Stably transfected 293 cells containing the vectors for each MRP/PLF were selected by 
detecting MRP/PLFs in conditioned medium by Western blots. Table II shows that after 
transacting the cells with pcDNA(His,EK)PLFl and pcDNA(His,EK)MRP3, 24% of the 
G418 resistant clones expressed detectable amounts of recombinant His-PLFl and His-MRP3, 
respectively. 
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His-MRP/PLFs Number Number of Numbers of % clones % clones 
of wells clones resistant clones expressing expressing His- resistant 
plated toG418 His-MRP/PLFs MRP/PLFs toG418 
His-PLFl 288 137 33 24 48 
His-PLF2 * 192 55 2 4 29 
His-MRP3 288 238 58 24 83 
His-MRP4 288 108 0 0 38 
* The pooled clones were cryopreserved before plating in 96 well plates. 
The pool of G418 resistant cells transfected with pcDNA(His,EK)PLF2 was 
cryopreserved prior to diluting and plating in the 96 well plates, which probably resulted in 
decreased cell viability leading to a decrease in His-PLF2 expressing clones. Clones of 293 
cells resistant to G418 were obtained when transfected with the plasmid 
pcDNA(His,EK)MRP4 suggesting that stably transfected cells were obtained. However, no 
clones expressed detectable amounts of secreted His-MRP4 by Western blot. This observation 
led to a further investigation of the putative MRP4 clones. 
MRP4 is not detected when expressed with the His-EK constructs 
During the construction of the pcDNA(His,EK)MRP4 plasmid, DNA sequencing 
revealed that the MRP4 cDNA contained a point mutation (position 155 from the start codon) 
that changed the original glycine52 codon (GGC) to an aspartic acid codon (GAC). Utilizing 
the QuickChange method (Stratagene), the original glycine codon was restored. This 
corrected cDNA was recloned into pcDNAS.l (-) which was then used for the transaction of 
293 cells as described above to obtain stable His-MRP4 expressing clones. Transient 
transactions in COS cells were used to further investigate the lack of His-MRP4 
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accumulation in the conditioned medium of 293 cells stably transfected with 
pcDNA(His,EK)MRP4. 
The plasmid cmv-mini-sis-MRP4, was transiently transfected in COS cells as a 
positive control for MRP4 expression and detection, as demonstrated by Fassett et al. (5). The 
rabbit anti-MRP/PLP serum 89Rbl3b used for Western blots was shown to detect MRP4 in 
the conditioned medium of transiently transfected COS cells and of placental extracts (5). 
COS cells transiently transfected with pcDNA(His,EK)PLFl could secrete and accumulate 
His-PLFl in the conditioned medium. However, similar to what was observed with stably 
transfected 293 cells, His-MRP4 could not be detected by Western blot in the conditioned 
medium of COS cells transiently transfected with pcDNA(His,EK)MRP4 (Figure 2). 
DNA sequencing showed that Cmv-mini-sis-MRP4 contained the mutated version of 
MRP4. To rule out the possibility that this point mutation was responsible for the inability to 
detect recombinant protein in conditioned medium, the mutated version of 
pcDNA(His,EK)MRP4 was also transiently transfected in COS cells. No accumulation of His-
MRP4 in the conditioned medium could be detected by Western blot (data not shown). 
Finally, to role out the possibility of detrimental mutations in the pcDNA vector itself, 
the expression cassette for (His,EK)MRP4 was reinserted in the pcDNA3.1(-) vector portion 
of the pcDNA(His,EK)PLFl construct. No detectable amounts of His-MRP4 could be 
detected by Western blot in the conditioned medium of COS cells (data not shown). 
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Figure 2: His-MRP4 cannot be detected in the conditioned medium of transiently transfected Cos cells. 
Western blot of conditioned medium collected 5 days after COS cells were transiently transfected with 5|Al of 
water: (H,0), pcDNA3.1(-): (Vec), pcDNA(His,EK)PLFl: (His-PLFl), pcDNA(His,EK)MRP4: (His-MRP4) or 
cmv-mini-sis-MRP4: (MRP4). The numbers represent the amount in Hg of plasmid used for the DEAE dextran 
transfection of 50 % confluent COS cells. The molecular weight markers used are defined in Materials and 
Methods. 
Optimization of culture conditions for maximal secretion 
The 293 cell clone secreting His-MRP3 was initially grown in 5 % calf serum. To 
decrease the amount of contaminating serum proteins for protein purification the clones were 
switched to serum-free conditions and His-MRP3 accumulation in the conditioned medium 
was tested. After reaching confluency, the 293 cell clones were rinsed with warm TBS and 
switched to serum free medium. Recombinant His-MRP3, detected by Western blot, 
accumulated in the conditioned medium and protein contaminants were detected by silver 
staining. More His-MRP3 was secreted when the medium contained 5% serum compared to 
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no serum, but a significant amount of His-MRP3 was still secreted in the absence of 
serum (Figure 3). The Western blot showed no detectable degradation products for His-MRP3 
suggesting that it is stable in the conditioned medium. Similar results were observed for His-
PLF1 (data not shown). 
Figure 3: Serum dependency of the secretion of His-MRP3 in the conditioned medium of a 293 clone. 
After reaching confluency the cells were washed with warm TBS. Medium containing 0 % or 5 % calf serum 
was added to the cells. For each time point an aliquot was taken, cell debris was removed by centrifiigation, and 
the supernatant was frozen until use. Panel A: SDS-PAGE of the conditioned medium followed by Coomassie 
Blue and silver staining. Indicated on the left are the molecular weights of the protein standards defined in 
Materials and Methods. Panel B: Duplicate samples were run in parallel and His-MRP3 was detected by 
Western blot. No other bands aside from the ones shown here were detected. 
Protein secretion can be stimulated in cells grown in serum free medium by adding a mixture 
of insulin, transferrin and selenium (14,15). To test if the cells would accumulate more 
recombinant proteins in the presence of these three medium supplements, they were added in 
different combinations. Figure 4 shows more recombinant His-MRP3 accumulated in the 
conditioned medium in the presence of insulin compared with no insulin regardless of the 
A 
B 
# 
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presence of transferrin and selenium. Thus, insulin alone was enough to increase the overall 
accumulation of proteins in the conditioned medium as seen by silver staining. 
From these results, the conditions for the highest His-MRP3 secretion with the lowest 
amount of serum contaminants were established as follows: The cells were grown to 
confluency in a medium containing 5 % serum, washed with warm TBS and switched to 
serum free medium supplemented with 5 |i,g/ml of insulin and the cells were incubated 8 days 
to secrete recombinant His-MRP3. Subsequently it was discovered that insulin at such high 
concentrations inhibited binding of His-MRP3 to the nickel affinity column (data not shown). 
Figure 4îAction of insulin, transferrin and selenium on the accumulation of His-MRP3 in the 
conditioned medium of stably transfected 293 cells. 
After reaching confluency the cells were washed with warm TBS and medium containing the different 
supplements was added. Insulin and transferrin were added at 5(ig/ml and selenium at 5 ng/ml. B: water, 
I: insulin, T: transferrin, S: selenium. IT: insulin and transferrin, IS: insulin and selenium, TS: transferrin and 
selenium, ITS: insulin, transferrin and selenium. Panel A: Silver stain of the conditioned medium resolved by 
SDS-PAGE followed by Coomassie Blue and silver staining. Indicated on the left are the molecular weights of 
the standards defined in Materials and Methods. Panel B: Duplicate samples were run in parallel and His-MRP3 
was detected by Western blot. No other bands aside from the ones shown here were detected. 
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To prevent problems during purification, His-MRP3 was accumulated in the absence of 
insulin in the medium. Similar results were obtained with the 293 clone expressing His-PLFl. 
Purification of recombinant His-MRP3 
The recombinant proteins were purified from the conditioned medium of a 293 cell 
clone expressing His-MRP3 by successive affinity chromatography fractionation on a nickel 
chelate column, a pea-lectin column, and a second nickel column. Detection of His-MRP3 in 
the different fractions was performed using Western blot with the rabbit antiserum 89Rbl3b. 
Purity was determined by Coomassie staining followed by silver staining. Typical yields were 
approximately 0.1 to 0.2 mg of protein per liter of conditioned medium (Table HI). 
TABLE 111: Purification profile of His-MRP3. 
Steps Fraction Total MRP Total Total Purity Yield 
Volume Protein Concentration Protei MRP (%)c (%)d 
(ml) (Hg/ml) (arbitrary)1 n 
(mg) 
(mg)" 
Conditioned Medium 4000 35 6 139 5.0 4 100 
After concentration/ 
Before Nickel I 
215 722 96 155 4.3 3 81 
After Nickel V 
Before Lectin 
38 179 201 7 1.5 21 28 
After Lectin/ 
Before Nickel II 
90 10 64 9 1.2 13 23 
After Nickel W 14 35 167 0.5 0.5 100 9 
Pooled fractions 
a: The arbitrary units correspond to the intensity (determined by densitometry) of the bands from the Western blot 
of figure 5. b: The total amount of His-MRP3 in each fraction was determined by assuming that all the proteins in 
the "pooled fractions" were MRP (see Figure 5). c: Purity: total MRP/Total protein, d: Yield: MRP/ Initial 
amount of MRP 
The recombinant His-MRP3 secreted by the 293 cell clone was recognized by the 
MRP/PLFs antiserum, indicating that the protein purified is immunologically similar to the 
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endogenous MRP/PLFs. The expected molecular weight of 35 to 41 kDa observed on the 
Western blot and silver stained gels (Figure 5) corresponds to the molecular weight of the 
native placental MRP/PLFs plus another 5 kDa corresponding to the histidine tag. The 
presence of the tag was confirmed by the specific binding of His-MRP3 to a nickel column. 
Finally, 293 cells stably transfected with empty pcDNA3.1(-) did not secret any proteins that 
His-EK' 
MRP 3 
Figure 5: Purification of His-MRP3. 
Panel A: Lane 1: conditioned medium before ultrafiltration. Lane 2: Concentrated medium before loading on the 
nickel column. Lane 3: pooled fractions containing His-MRP3 post-first nickel column and pre-lectin column. 
Lane 4: Pooled fractions containing His-MRP3 post-Iectin column and pre-second nickel column. Lane 5: Pooled 
fractions containing His-MRP3 after the second nickel-chelate column. Panel A: The different fractions of the 
purification scheme were loaded at equal volume on SDS-PAGE followed by Coomassie staining and silver stain. 
The numbers on the side indicate the molecular weight in kDa of protein standards defined in Materials and 
Methods. Panel B: Duplicate samples were run in parallel and His-MRP3 was detected by Western blot No other 
bands aside from the one shown here were detected. 
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were recognized by the MRP/PLF antiserum. This demonstrates that the protein purified was 
not a contaminant from the conditioned medium of 293 cells which could cross react with the 
MRP/PLF antiserum (data not shown). These results provide evidence that the isolated 
protein is in fact the recombinant His-MRP3 glycoprotein. Using the same purification 
protocol, His-PLFl was isolated from the conditioned medium of the 293 clone stably 
transfected with the pcDNA(His,EK)PLFl plasmid with yields comparable to the ones for 
His-MRP3. 
Enterokinase treatment of His-EK-MRP3 to obtain histidine tag free MRP3 
The pcDNA(His,EK)PLFl, pcDNA(His,EK)PLF2, pcDNA(His,EK)MRP3 and 
pcDNA(His,EK)MRP4 plasmids were constructed to include an enterokinase cleavage site to 
allow the removal of the histidine tag. Figure 6, Panel A, shows a time course of enterokinase 
digestion to determine the optimal incubation time. By scanning densitometry of the film from 
the Western blot it appeared that within the first 24 hours 33 % of the starting protein was 
lost. At 48 hours, 53 % was lost and at 72 hours 65 % was lost Panel B of Figure 6 shows 
that enterokinase digested MRP3 can be successfully separated from the undigested His-
MRP3 by the use of a nickel affinity column to retain any undigested His-MRP3. The typical 
recovery of digested MRP3 was about 15 % of the starting amount of His-MRP3 as 
determined by Coomassie plus protein assay (Pierce). His-MRP3 incubated under identical 
buffer conditions without the enzyme did not show any detectable degradation (data not 
shown). 
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Figure 6: Enteroldnase cleavage of the histidine tag from purified His-MRP3. 
Western blot showing cleavage of the histidine tag from His-MRP3 over time. Purified His-MRP3 was incubated 
at room temperature for the indicated time in the presence of 1 Jig of recombinant enterokinase. Panel A: shows 
the time course. Panel B: represents the separation of the cut MRP3 using the nickel column to retain the 
undigested His-MRP3. 
DISCUSSION: 
Recombinant MRP3 and PLF1 were expressed and purified by N-terminal histidine 
lagging by first concentrating the conditioned medium of transacted 293 human fetal kidney 
cells by ultrafiltration. The histidine tagged MRP/PLFs were then purified and further 
concentrated using three affinity chromatography steps (Nickel chelation, pea-lectin, and 
another Nickel chelation). The histidine tag can be removed by enterokinase digestion 
releasing the untagged MRP/PLFs. The stably transfected 293 cells expressed a glycosylated 
form of PLF1 and MRP3, with a molecular weight range similar to the one observed for 
placental MRP/PLFs. This is the first report that glycosylated recombinant MRP3 has been 
expressed and purified to homogeneity. The yields obtained by this methodology are 
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comparable to those reported by Lee and Nathans (16) who purified glycosylated recombinant 
PLFl from CHO cells stably transacted with a plasmid construct containing the 
metallothionein I promoter upstream of the PLFl cDNA. The advantages of the added 
histidine tag was demonstrated by the fewer steps used in this method as compared to Lee and 
Nathans (16). In addition, if binding of the histidine tagged proteins to the MRP/PLF receptors 
can be demonstrated, it could allow for a convenient in situ detection method utilizing either 
anti-poly histidine antibodies or a nickel-HRP detection system, both commercially available. 
The decision to add a N-terminal histidine tag to the MRP/PLF recombinant proteins, 
was made by studying the tertiary structure of human growth hormone bound to its 
receptor (17). Growth hormone is a member of the prolactin/growth hormone family and PLFl 
is 21 % identical and 35 % homologous to human growth hormone deduced cDNAs. The 
crystal structure of growth hormone showed the N-terminus was less structured and pointed 
away from the bulk of the molecule, whereas the C-terminus was not as available and was 
associated in the binding to the receptor (17). In addition, a chimera of human alkaline 
phosphatase attached to the N-terminus of rat placental lactogen ! was constructed and 
expressed in 293 cells to detect binding to lactogenic receptors via its phosphatase activity 
(18). Placental lactogen I is a member of the prolactin/growth hormone family and the chimera 
secreted by 293 cells bound to the prolactin receptor and stimulated Nb2 cell proliferation via 
the prolactin receptor. Alkaline phosphatase activity could be detected in situ specifically 
where placental lactogen I binding was demonstrated (18). The results of these studies showed 
that the addition of alkaline phosphatase to the N-terminus of placental-lactogen I and the 
expression in 293 cells were compatible with receptor binding. Other members of the 
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prolactin/growth hormone family: prolactin-like protein A (19), decidual/trophoblast 
prolactin-related protein (20) were also successfully engineered with the alkaline phosphatase 
at their N-termini, suggesting that a N-terminus histidine tag might not disrupt MPR/PLF 
binding to its receptors. 
The histidine tag on His-MRP/PLF can be removed using the enterokinase recognition 
sequence in case the additional N-terminus amino acid residues would prevent the MRP/PLF 
proteins from binding to their receptors. The recovery of enterokinase digested MRP3 was 
very low with the loss primarily occurring during the first 24 h of incubation with 
enterokinase. MRP/PLFs are stable proteins at room temperature and can accumulate in the 
conditioned medium of cells. The presence of the histidine tag did not seem to have any 
deleterious effect as His-PLFl and His-MRP3 were stable under the purification conditions. 
His-MRP3 incubated without the enterokinase, under the same conditions used for 
enterokinase digestion, did not undergo the rapid loss observed when the enterokinase is 
present (data not shown). No other enterokinase recognition sites are present in the mature 
MRP/PLFs that would account for the rapid loss of protein during the first 24 hours of 
digestion. An additional observation (Nelson, unpublished results) indicated that MRP/PLFs 
purified from 3T3 cells was readily lost by adsorption to the surface of tubes. It is possible 
that the loss of protein observed during the enterokinase cleavage was due to preferential 
adsorption of the cut MRP3 to the side of the tubes during the first 24 h of incubation. 
Although insulin increased secretion of recombinant His-MRP/PLFs, this increase was 
compromised by an accompanying insulin-mediated inhibition of His-MRP/PLF binding to 
the nickel column. This inhibition was directly demonstrated by the addition of 5 |i.g/ml 
insulin to the binding reaction inhibiting the binding of His-PLFl to a nickel column (data not 
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shown). Nickel ions in solution have been found in complexes with insulin as hexamers and 
trimers (21). This suggests that insulin with a binding affinity for nickel ions would effectively 
block histidine tagged protein binding to the nickel chelate column. 
The lack of accumulation of His-MRP4 in the conditioned medium of either 293 or 
COS cells was unexpected. Why MRP4 did not accumulate in the conditioned medium of 
these cells is unclear, especially knowing that MRP4 is 97 % identical at the cDNA level and 
91 % identical at the protein level to the other known MRP/PLFs. From the transient 
transactions experiments using COS cells, MRP4 can in fact accumulate in in vitro culture 
medium denoting stability of the protein in these conditions. The point mutation changing the 
original glycine52 to aspartic acid in the secreted protein is not responsible for the absence of 
His-MRP4 in the conditioned medium as the mutated His-MRP4 does not accumulate either. 
The positive control for MRP4 secretion by COS cells was the plasmid cmv-mini-sis-MRP4 
used by Fassett et al (5). This plasmid contains several features absent in the plasmid construct 
pcDNA(His,EK)MRP4 used here, including a MRP3 signal sequence followed by a hybrid 
intron (22) linked to the MRP4 cDNA then followed with the MRP3 3' untranslated region. It 
is unclear if these added features are responsible for the accumulation of MRP4 in conditioned 
medium or if the histidine tag specifically prevents MRP4 accumulation compared to the other 
MRP/PLF proteins. The role of the histidine tag could be tested by transient transfections of 
COS cells with the MRP4 cDNA without the histidine tag in the plasmid pcDNA3.1(-). If the 
histidine tag does not prevent the accumulation of MRP4, the role of the different elements of 
the cmv-mini-sis-MRP4 plasmid could be tested to determine which one(s) allows the 
accumulation of MRP4 in the conditioned medium. 
Purification of glycosylated recombinant PLFl and MRP3 in milligram quantities will 
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allow further testing of the roles of MRP/PLFs. The interactions of MRP/PLFs with their 
receptors is of special interest to the Nilsen-Hamilton laboratory and should shed light on their 
roles during gestation and wound healing. The two amino acid difference between the MRP3 
and PLFl proteins suggests that both could act through the same receptor. Comparing the plfl, 
mrp3 and mrp4 promoters, the mrp3 promoter is the only one to be specifically up-regulated 
by basic fibroblast growth factor in Swiss 3T3 cells (23). It will be interesting to know if the 
activities of MRP/PLFs are regulated only at the promoter level, or if regulation can also occur 
at the receptor level. 
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CHAPTER 3. 
STUDY OF THE ROLES OF MRP/PLFS DURING GESTATION AND 
BINDING OF PURIFIED MRP/PLFS TO THEIR RECEPTORS 
ABSTRACT: 
MRP/PLFs are glycoproteins expressed at high concentration during mid-gestation 
(day 10 to 14 after fertilization) in the placenta. A proposed role for MRP/PLFs during 
gestation is the stimulation of angiogenesis and uterine cell growth. To provide insights into 
the potential regulation of uterine cell proliferation by MRP/PLFs, the profiles of the wet 
weight and DNA content of the uterus were characterized and compared to an existing profile 
of MRP/PLF expression during gestation. Uterine DNA and wet weight increased rapidly 
between day 9 and 14 supporting the proposed role for MRP/PLFs in uterine cell growth 
during this period. Additionally, steroid profiles in the uterus and placenta were also compared 
to their plasma concentrations and MRP/PLF expression during gestation. In both the uterus 
and the placenta, estradiol-1?P concentrations were high (71 pg/mg in the uterus and 197 
pg/mg in the placenta) at gestational day 6 and low from day 8 to day 18 except for a small 
peak at day 14 (around 40 pg/mg in both uterus and placenta). The progesterone 
concentrations, in both the uterus and the placenta, were low except for a peak at day 10 (427 
pg/mg in the placenta, 142 pg/ml in the uterus). Direct examination of MRP/PLF stimulation 
by estradiol-17(3 or progesterone in day 8 and 9 placental minced, organ cultures 
demonstrated no effect on secreted MRP/PLF levels. Different preparations of purified 
MRP/PLFs were used to further study the uterine MRP/PLF receptor on primary uterine cell 
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and organ cultures, and in an in vitro day 11 uterine membrane binding assay. No evidence of 
biological or binding activity to the uterine MRP/PLF receptor was detected. MRP/PLF has 
also been shown to bind embryonic tissues during gestation. To further investigate whether 
MRP/PLF binding was due to localized synthesis within the embryo or export from the 
placenta, Northern blot and RT-PCR analyses were performed. No mRNA for mrp/plf could 
be detected in whole embryos (gestational day 11 to day 19) nor in total RNA from embryonic 
spines (gestational day 13 to day 19). This data supports the model that MRP/PLFs are not 
produced by the embryo but instead may be imported from the placenta. 
INTRODUCTION: 
The MRP/PLF family of glycoproteins is secreted by the trophoblastic giant cells 
during mid-gestation (1). The following studies have suggested that MRP/PLF can function as 
stimulators of angiogenesis and uterine cell proliferation. For instance, in the zinc finger 
transcription factors, GATA 2 or GATA 3, knockout mice, the decrease of MRP/PLF 
secretion from the placenta was shown to correlate with a decrease in decidual neo­
vascularization (2). Jackson et al., showed that recombinant PLFl could stimulate endothelial 
cell migration (3). Nelson et al. demonstrated the presence of a MRP/PLF binding activity 
from uterine membrane vesicles and demonstrated that the addition of MRP/PLF could 
stimulate DNA synthesis of primary uterine cells (4). These observations suggest that 
MRP/PLFs could be involved in the proliferation and neo-vascularization of the decidua 
during mid-gestation. 
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The ovarian steroids, estrogen and progesterone are known to play crucial roles in the 
preparation of the uterus for implantation during gestation (5). Estrogen is thought to mediate 
its action on the uterus indirectly via epidermal growth factor (EGF) (6,7), transforming 
growth factor-alpha (TGFa) (8,9) and other members of the EGF family (10). Progesterone, 
stimulates proliferation of the stromal cells of the uterus during the peri-implantation 
period (11, 12). In addition, progesterone is thought to have an anti-inflammatory effect in the 
uterus (13) and plays a role in regulating the immune system by decreasing natural killer cell 
activity (14,15). Interestingly, estradiol-17(3 was shown to increase the level of mrp/plf 
mRNA in sub-confluent BN/L liver cells, suggesting a possible regulation of MRP/PLF 
expression by steroids (16). However, the reported plasma levels of estradiol-170 and 
progesterone in the plasma (17) do not correlate with the rapid increase in MRP/PLF mRNA, 
at gestational day 10 to 14, in the placenta (18). Yet, the concentration of these steroids in the 
uterus and the placenta during gestation is unknown. Therefore, the levels of estrogen and 
progesterone throughout gestation were measured in the maternal serum, placenta and uterus 
using radioimmunoassays (RIA). The accumulation of MRP/PLF in the conditioned medium 
of placental organ cultures was also measured in response to treatment with progesterone and 
estradiol-17p. 
The uterus undergoes decidualization, at mid-gestation, which is characterized by the 
rapid multiplication and differentiation of the uterine stromal cell population, a massive 
infiltration of leukocytes (19,20) and an increase in vascular permeability (21). However, the 
overall relationship of uterine DNA content and mass during gestation is unknown and was 
examined. Measurement of the DNA content and wet weight of the uterus showed a rapid 
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increase, during mid-gestation, correlating with the expression profile of MRP/PLFs which 
also increased during mid-gestation. This observation supports the hypothesis that MRP/PLFs 
could play a role in the decidualization of the uterus which takes place during mid-gestation. 
Particularly, Fang et al. showed that MRP3 is the highest secreted member of the MRP/PLF 
family by the placenta (22) and therefore MRP3 was preferentially examined here, for its role 
in gestation. 
Nelson et al. showed that MRP/PLF isolated from 3T3 cells increased thymidine 
incorporation in uterine primary cell culture indicating an upregulation in cell proliferation (4). 
To examine the signaling mediated by MRP/PLFs, different preparations of purified 
MRP/PLFs, including His-PLFl and His-MRP3 (Chapter 2), were tested in binding assays for 
the MRP/PLF uterine receptor in vivo, utilizing uterine primary cell cultures and minced 
uterine organ cultures. No increase in thymidine incorporation in primary uterine cell cultures 
was observed after addition of MRP/PLFs. To verify that recombinant His-MRP3 could bind 
to the MRP/PLF uterine receptor it was tested for binding to day 11 uterine membrane 
preparations under the conditions reported by Nelson et al. (4). His-MRP3 was also 
characterized to test its binding activity to the insulin-like growth factor H /mannose-6-
phosphate (IGFH/M6P) receptor in the binding assay developed by Lee et al. (23). The 
receptor binding assay is based on the observation that recombinant PLFl could bind to the 
IGFD/M6P receptor purified from day 16 liver membrane preparations (23). Binding of PLFl 
could be competitively blocked by mannose 6-phosphate suggesting that binding occurred via 
the mannose 6-phosphate site of the receptor. 
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Additional roles for MRP/PLFs in angiogenesis and DNA synthesis in the embryo 
itself have been hypothesized. Preliminary data has shown the presence of mrp/plfmRNA in 
the embryo, suggesting that the MRP/PLF protein detected in the embryonic tissues could be 
synthesized in the embryo directly (24). MRP/PLF binding in the embryo could be detected in 
the heart, and endothelial cells of blood vessels from the developing vertebrae and ribs 
between day 10 and day 18 of gestation. However, mRNA synthesis of mrp/pif was 
undetectable in this study, suggesting that MRP/PLF protein was not locally synthesized in the 
embryo (25). The presence of MRP/PLF in embryonic tissues was further investigated by 
studying the type and gestational profile of mrp/plf mRNA in the embryo. 
MATERIALS AND METHODS: 
Animals and reagents 
Female CF1 mice, from a colony derived from animals originally obtained from 
Charles River Laboratories, Inc., were maintained as a breeding colony for the Nilsen-
Hamilton laboratory in one of the Iowa State University animal facilities, with a 12 h light, 
12 h dark cycle and food and water ad libitum. All animals were housed and treated according 
to current NIH guidelines. The research reported here was conducted in accordance with the 
standards set forth in the NIH Guide for the Care and Use of Laboratory Animals. Prior 
approval was obtained from the Iowa State University Committee on Animal Care for all 
procedures performed on the animals used in these studies. Animals were killed by cervical 
dislocation or C02 asphyxiation before removal of tissues for the described studies. The 
detection of a copulation plug was used to determine day 0 of gestation. 
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All tissue culture supplies were from Gibco Invitrogen Corporation, unless otherwise 
specified. Fetal bovine serum was purchased from Summit Biotechnology. Recombinant IGFII 
(r-IGFII) was purchased from R&D Systems. The IGFIIZM6P receptor was a gift from Dr G. 
Sahagian (Tufts University School of Medicine, Boston, MA). 
Quantitation of uterine DNA during gestation 
Uteri were dissected from female mice at various stages of gestation; each sample 
included both uterine horns. The total weight was recorded and the tissue was frozen in liquid 
nitrogen. Random sections of the uterus were cut, weighed and homogenized in ice cold 0.5 N 
perchloric acid using a Tissumizer (Tekmar). The homogenate was centrifuged at 12,000 x g 
for 2 min at 4 °C, resuspended in 0.5 N perchloric acid and hydrolyzed at 90 °C for 30 min. 
After centrifugation for 2 min at 12,000 x g and 4°C, the supematants were diluted 1/2.5, 1/5, 
1/10 and 1/20 in 0.5 N perchloric acid and their DNA content was analyzed using the 
diphenylamine-colorimetric method (26, 27). A standard DNA curve was made for each assay 
from a stock of 0.2 mg/ml salmon sperm DNA type HI (Sigma) in 0.5 N perchloric acid. 
Different stocks of DNA standards were normalized to each other by measuring their 
absorbance at 260 nm. Diphenylamine reagent (1.5 g diphenylamine dissolved in 100 ml of 
glacial acetic acid and 1.5 ml of concentrated sulfuric acid) was prepared fresh and 0.1 ml of 
1.6 % of aqueous acetaldehyde was added just prior to use. One ml of the diphenylamine 
reagent (with acetaldehyde) was added to 0.5 ml of uterine sample supernatant or DNA 
standard and the color was developed at 30 °C for 15 to 17 hours. The absorbance of the 
samples was measured at 600 nm in a DU62 spectrophotometer (Bee km an) 
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Estradiol-17 fi and Progesterone analysis 
Mice at known gestational stages were sacrificed by cervical dislocation. Immediately 
after death, a sample of systemic blood was collected by heart puncture in a syringe containing 
heparin at a final concentration between 15 and 50 U/ml. Plasma was prepared by 
centrifugation for 5 min at 12,000 x g and the supernatant was stored at -20 °C. The uterus was 
removed and samples of both placental and uterine tissues associated with each fetus were 
collected, rinsed in TBS (140 mM NaCl, 8 mM Na^HPO,, 2.7 mM KC1, 1.5 mM KH2P04, 
0.68 mM CaCl2,0.5 mM MgCl, pH 7.5), weighed and immediately frozen under liquid 
nitrogen. The tissue homogenization and radioimmunoassays (RIA) for estradiol-17(3 and 
progesterone were done by Carole Hertz from the laboratory of Dr S. Ford (Iowa State 
University) as part of a collaboration. Tissue samples were homogenized in 1 ml deionized 
water using a tissue homogenizer (TissueTearor), and frozen at -20 °C until assayed for 
estradiol-l7(3 and progesterone by RIA. Aliquots of all placental homogenates, and aliquots of 
all uterine homogenates from a pregnant female were pooled to form a single placental tissue 
pool and a single uterine tissue pool. An aliquot of each tissue pool (placental and uterine) was 
then extracted and assayed for estradiol ! 7(3 (28) and progesterone (29). Estradiol-17(3 and 
progesterone in systemic plasma was also quantitated by RIA (29). Tissue or plasma samples 
from different days of gestation were evaluated together in the same RIA to decrease errors. 
Values were normalized to mg of wet weight of tissue. 
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Minced placental tissue culture 
Mice at known gestational stages were sacrificed and placentae were collected and 
minced to approximately 1-mm3 pieces using two scalpel blades. After rinsing with TBS the 
minced tissues were centrifuged at 500 x g for 5 min at room temperature. The pellet was 
rinsed and centrifuged once more. The resulting pellet was resuspended in DMEM high 
glucose without phenol red supplemented with fetal bovine serum treated with 2 % dextran-
coated charcoal to eliminate endogenous steroids, 50 U/ml penicillin/streptomycin, 20 mM 
HEPES. After addition of estradiol-170 or progesterone, the minced tissues were incubated at 
37 °C in 5 % C02 for 24 h. The conditioned medium was collected and clarified by 
centrifugation at 12,000 x g for 5 min at room temperature RT. The presence of MRP/PLFs in 
the conditioned medium was detected by Western blot. 
Western blot analysis and densitometry 
MRP/PLF containing samples were diluted in 2 x sample buffer (0.125 M Tris, 20 % 
glycerol, 0.01 % bromophenol blue, 4 % SDS, pH 6.9) and boiled for 10 min. The samples 
were resolved by SDS-PAGE on a 12.5 % acrylamide gel and electrophoresis was completed 
at 35 mA for 3 h in 0.4 M glycine, 50 mM Tris-HCl, 1 % SDS pH 8.35. The molecular weight 
markers were bovine serum albumin (66 kDa), ovalbumin (45 kDa), carbonic anhydrase 
(33 kDa), myoglobin (18 kDa) and cytochrome c (12.5 kDa). The proteins were transferred 
onto a nitrocellulose membrane (Nitrobind 0.45 |lm, Osmonics) using a Hoefer TE50 
apparatus at 30 V for 12 h at 4 °C in transfer buffer (25 mM Tris, 190 mM glycine, 20 % 
methanol, pH 8.3). The membrane was stained with 0.2 % Ponceau S in 3 % trichloroacetic 
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acid to ascertain uniform transfer of proteins to the membrane. After destaining with water, 
the membrane was incubated for 30 min at 37 °C in blocking solution (5 % wt/vol nonfat milk 
in 0.14 M NaCl, 5 mM KC1,0.7 mM NajHPO,,, 25 mM Trizma pH 7.5,0.02 % wt/vol sodium 
azide). The blocking solution was removed and replaced with fresh blocking solution 
containing rabbit antiserum 89Rbl3b (raised against MRP/PLFs purified from 3T3 cells) at a 
final dilution of 1/200. This polyvalent antiserum is immunoreactive to PLFl, PLF2, MRP3 
and MRP4. After incubation at room temperature for 90 min, the membrane was washed three 
times (10 min each) in wash buffer (140 mM NaCl, 2.7 mM KC1, 1.5 mM KH2P04, 8 mM 
NagHPO,, pH 7.5). The first wash contained 0.1 % Tween 20. The membrane was then 
incubated for 30 min at room temperature with 8 ng/ml of goat anti-rabbit IgG conjugated to 
peroxidase (Pierce) in wash buffer. The membrane was washed three times (10 min each) in 
wash buffer, with the first wash containing 0.1 % Tween 20. The presence of peroxidase 
activity was detected by enhanced-chemiluminescence using ECL™, (Amersham Pharmacia) 
and exposure of X-ray film (Kodak). 
RNA isolation, Northern Blotting and RT-PCR 
Total RNA was isolated from 50 to 100 mg of frozen tissue using TRIzol® reagent 
(Gibco, Invitrogen Corporation) and resuspended in RNAse free water. Total RNA, 15 to 
30 |ig determined by absorption at 260 nm, was dried using a vacuum centrifuge (SpeedVac, 
Savant) and the pellet was resuspended in 15 pi of RNA loading buffer (48 % formamide, 
0.11 M MOPS, 6.4 % formaldehyde, 5.3 % glycerol, 0.25 % bromophenol blue). The samples 
were boiled 2 min and loaded onto a 1 % agarose gel, containing 1.7 % formaldehyde, 
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0.5 p.g/ml ethidium bromide. Electrophoretic separation was completed at 60 V for 3 h in 
0.2 M MOPS, 50 mM sodium acetate, 10 mM EDTA pH 7.0. The gel was rinsed at room 
temperature 15 min in deionized water followed by 15 min in 50 mM NaOH. The RNA was 
transferred to Zeta-Probe® GT Blotting membrane (Bio-Rad) by alkaline capillary transfer 
overnight in 50 mM NaOH. The membrane was washed 10 min with 2X SSC (IX SSC: 
0.15 M NaCl, 15 mM sodium citrate pH 7.0) and baked 15 min at 80 °C under vacuum. Before 
probing, the membrane was pre-hybridized at 47 °C for 6 h with 100 |lg/ml yeast tRNA and 
salmon sperm DNA, boiled 2 min and chilled on ice, in 0.6 M NaCl, 40 mM NaH2P04, 
50 mM EDTA, 7 % SDS, 1 % PEG 20000,40 % formamide, 0.1 % NP40, pH 7.4. A 32P-
labeled mrp/plf probe was generated by using the Multiprime DNA labeling system 
(Amersham Pharmacia), mrp3 cDNA and 3000Ci/mmol a-32P-dCTP (ICN). Unincorporated 
dNTPs were separated from the labeled probe by gel filtration using a micro bio-spin P-30 
Tris chromatography column (Bio-Rad). The probe in 10 mM Tris pH 7.4 was boiled 5 min 
and chilled on ice before adding to the blot in the pre-hybridization solution for a 16 h 
incubation at 47 °C. The membrane was washed twice for 15 min with 0.5X SSC, 0.1 % SDS 
at room temperature followed by 2 washes for 15 min with 0.2X SSC, 0.1 % SDS at 47 °C. 
The membrane was dried and exposed to a Phosphorlmager screen at room temperature. The 
screen was scanned and quantitated using a Phosphorlmager 400A and the ImageQuant 3.3 
software (Molecular Dynamics). 
The "house-keeping" gene glyceraldehyde-3-phosphate dehydrogenase (gpdh) was 
used to normalize RNA loading. Before reprobing, the 32P-mrp/plf probe was removed from 
the membrane by boiling the membrane twice for 3 min in 0.1 X SSC, 0.1 % SDS. The 
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stripped membrane was pre-hybridized, hybridized with a 32P-labeled gpdh probe, washed and 
exposed to a Phosphorlmager screen as described above. 
RT-PCR using the SuperScript™ One-Step RT-PCR kit from Invitrogen Life 
Technologies was performed on 1 |lg of total RNA. Mrp/plf cDNAs were amplified using 
0.2 \lM of the primers Del (5' TAAGCCTGGGTAGGACTCTGC 3 ) and Ue5 ( 5' 
TTCAGAAGCAGAGC ACATGAAA 3 ). Gpdh cDNA was amplified using 0.2 |iM of the 
primers GPDH5 (5* TGT GGATGGCCCCTCTGGAAA 3 ) and GPDH3 (5' 
GTTTCTTACTCCTTGGAGGC 3').The cDNA synthesis was done at 50 °C for 30 min 
followed by a pre-denaturation step at 94 °C for 2 min. The PGR amplification consisted of 40 
cycles (94 °C for 15 s, 60 °C for 30 s, 72 °C for 50 s) and a final extension step at 72 °C for 
10 min using the DNA engine Opticon (MJ Research). The RT-PCR products were resolved 
on a 1.5 % agarose gel, containing 0.5 lig/ml ethidium bromide, using TAE buffer (40 mM 
Tris, 40 mM acetic acid, 1 mM EDTA pH 8.5) at 80 V for 1 h. 
Primary mice uterine cell and minced uterine cell cultures 
Primary uterine cells were isolated using two different methods. The first was 
developed by Rosenzweig (Nilsen-Hamilton laboratory) and is a modified version of an earlier 
method (30). The uteri were removed from the mice and separated from the placentae and 
embryos in sterile conditions. The uteri were rinsed in Ca2>, Mg2* free Hank's balanced salt 
solution (HBSS), cut in smaller pieces and incubated in 0.25 % Trypsin, 1 mM EDTA in TD 
at 4°C for 12 h in a 50 ml conical tube (Coming). The trypsin solution was discarded and the 
tissue was left in the tube and incubated at 37 °C for 1 h. The uteri were covered with HBSS 
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and vortexed at the highest setting for 5 min. The HBSS was collected and the remaining 
tissue was rinsed with fresh HBSS. Both fractions were collected and centrifuged at 1,000 x g 
for 10 min. The cell pellet was vigorously resuspended with HBSS containing 0.3 % bovine 
serum albumin (Sigma). The clusters of epithelial cell settled at 1 x g for 10 min in a narrow 
tube at 37 °C. The supernatant fraction, enriched with the stromal cells, was transferred to a 
fresh tube and centrifuged for 5 min at 1,000 x g. The cell pellet was resuspended in growth 
medium (DMEM high glucose supplemented with 10 % heat-inactivated fetal bovine serum, 
20 U/ml penicillin/streptomycin, 10 ng/ml bovine insulin) and the cells were seeded in a 24 
well tissue culture plate at a concentration of 2 xlO5 cells per well. Half of the medium was 
replaced with fresh growth medium every 48 h. After 3 to 4 days of growth at 37 °C in 
10 % CO;, the cells were confluent. Growth factor additions were made by replacement with 
fresh growth medium. 
The second method for isolating uterine stromal cells was done according to 
McCormack and Classer (31). The uteri were isolated, cut in smaller pieces and washed as 
described above, then incubated in a 50 ml conical tube (Coming) with 0.5 % Trypsin, 
2.5 % pancreatin in HBSS for 90 min at 4 °C followed by 30 min at room temperature. The 
tissues were vortexed 15 s at setting 5 (Fisher vortex genie 2), the supernatant containing the 
epithelial cells was removed and the remaining tissue pellet was rinsed with HBSS. The tissue 
pellet was transferred to a 15 ml conical tube (Coming) containing five sterile 5-mm glass 
beads and 0.25 % Trypsin, 1 mM EDTA in TD. The tissues were incubated at 37 °C for 
15 min with 10 s vortexing at setting 5 (at the beginning, middle and end of the incubation). 
The cells were centrifuged and washed once with HBSS at 1,000 x g for 10 min. The stromal 
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cell enriched pellet was resuspended in growth medium and plated as described above at 
2 xlO5 cells per well. 
The method used for minced uterine cell cultures was developed by Rosenzweig 
(Nilsen-Hamilton laboratory). Each fetus in utero were separated from each other and the 
uterine section was separated from the fetus and associated placenta. Each section of uterine 
tissue was placed in an individual well of a 24 well tissue culture plate containing DMEM 
high-glucose supplemented with 2 % fetal bovine serum, 50 U/ml penicillin/streptomycin and 
20 mM HEPES pH 7.5. The uterine tissue were maintained in culture medium at 37 °C in 
5 % C02. 
Thymidine incorporation assay 
Primary uterine cell cultures were prepared according to the protocols described above. 
The cells were plated on coverslips prepared by successive boiling in Calgon (8.8 g/1 Calgon, 
79 g/1 sodium metasilicate), rinsing in distilled water, boiling 10 min in distilled water, rinsing 
in distilled water, then a final rinse in absolute ethanol. After drying the coverslips were heat 
baked sterilized for 4 h at 350 °C. 
When the primary uterine cell cultures were confluent, the medium was replaced with 
fresh growth medium containing different growth factors. The primary uterine cells were 
incubated for 26 h followed by an additional 4 h pulse with 8 |iCi/ml of methyl-3H-thymidine 
(ICN). Upon completion of the incubations, the medium was removed, the cells were washed 
twice with 0.5 ml of TBS followed by fixation overnight at room temperature with 3.7 % 
formaldehyde in 85 mM NaCl, 0.1 M Na,SO4. After removal of the fixative, the cells were 
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incubated in 0.5 ml of 10 % trichloroacetic acid (TCA) at 4 °C for 30 min. The cells were 
rinsed with 1 ml of 95 % ethanol followed by a 5 min dehydration step in 1 ml of 95 % 
ethanol. The cell-covered coverslips were removed and placed in scintillation vials to dry for 1 
h. Five ml of Scintiverse BD cocktail (Fisher) was added and the tritium incorporated by the 
cells on coverslips was detected in a Liquid Scintillation Analyzer (Packard 1900TR). 
For thymidine incorporation in minced uterine tissue culture, 8 |iCi/ml 3H-thymidine 
was added with MRP/PLFs directly after the tissue was placed in growth medium. After 30 h 
the growth medium was removed and the tissues were rinsed twice for 10 min in 0.5 ml TBS 
and 0.5 ml of 10 % trichloroacetic acid for 30 min at 4 °C. The tissues were rinsed in 1 ml of 
95 % ethanol followed by a 30 min dehydration step in 1 ml of 95 % ethanol. After removing 
the ethanol the tissues were air dried overnight, weighed and placed in a scintillation vial with 
5 ml Scintiverse BD cocktail. The thymidine incorporated in the tissues was detected in a 
Liquid Scintillation Analyzer (Packard 1900TR). 
125Iodine labeling of MRP3, r-IGFH, IGFII/M6P receptor 
Purified His-MRP3 or MRP3 (Chapter 2), r-IGFH and IGFD/M6P were iodinated using 
Iodo Beads (Pierce). Typically, 25 to 50 |ig of purified protein was labeled with 0.25 to 
0.5 mCi of l23Iodine (ICN) for 15 min using one bead. Unincorporated iodine was separated 
from labeled proteins by size exclusion chromatography using a 10-DG column (Bio-Rad) 
equilibrated with 25 mM Tris pH 7.6. Iodinated proteins were eluted with 25 mM Tris pH 7.4 
into 1 ml fractions, for His-MRP3 and MRP3, BSA was added to the fractions at 0.1% final 
to stabilize the iodinated proteins. The fractions containing the iodinated protein were pooled 
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and purity was determined using SDS-PAGE and autoradiography. The iodinated proteins 
were analyzed by TCA precipitation before use to determine the total precipitable counts. 
Membrane isolation and receptor binding assay 
Membrane preparations of day 11 uterus were prepared according to Nelson et al. (4) 
and membranes from day 16 livers were prepared according to Lee and Nathans (23). Briefly, 
uterus or liver tissue were dissected and rinsed in 0.3 M sucrose with all subsequent steps 
performed at 4 °C. The tissues were homogenized using the Tissumizer (Tekmar) at a setting 
of 50 for 4 min followed by 1 min at full speed. The homogenate was centrifuged at 3,000 x g 
for 20 min and the supernatant obtained was further centrifuged at 10,500 x g for another 
20 min. This supernatant was then centrifuged at 100,000 x g for 90 min. The pellet 
containing the uterine membranes was resuspended in 250 mM Tris-HCl, 10 mM MgCl2 pH 
7.6. The pellet containing the liver membranes was resuspended in 25 mM Tris-HCl, 10 mM 
MgCl^pH 7.6. The total protein content was determined using the Coomassie Plus Protein 
assay (Pierce) and both membrane preparations were aliquoted and stored at -80 °C 
The receptor binding assays on uterine membranes were done according to the method 
described by Nelson et al. (4). Briefly, 0.1 to 0.5 mgZml of uterine membrane was incubated 
with l25I-His-MRP3 or 125I-MRP3 in Tris buffer-250, (250 mM Tris-HCl, 10 mM MgCl2, 
pH 7.6) containing 1 % bovine serum albumin, 10 mM mannose 6-phosphate, 2 mM NaCl, 
0.08 mM CaCl2 at RT for 90 min. Specific binding was determined by adding 100-fold excess 
unlabeled His-MRP3 or MRP3 to the reaction mixture. One ml of cold Tris buffer-250 was 
added and the diluted mix was filtered under vacuum on Durapore filters (GVWP 02500, 
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0.22 [im, Millipore). The filters were washed 6 times with cold Tris buffer-250. The filters 
were dried 1 h at RT, 5 ml of Scintiverse BD cocktail (Fisher) was added and the 125Iodine 
counts were measured using a Liquid Scintillation Analyzer (Packard 1900TR). 
The liver membrane binding assay was done according to Lee and Nathans (23). 
Briefly, 2 to 100 Hg/ml of liver membrane was incubated with 125I-His-MRP3, l25I-MRP3 or 
,25I-IGFII in Tris-HCl pH 7.6 containing 5 mg/ml bovine serum albumin, 6 mM EDTA, 0.04 
mM MgCl2 at 4 °C for 12 to 18 hours. Specific binding was determined by adding 10 mM 
mannose 6-phosphate or 10 to 100 fold non-labeled IGFII to the reaction mixture. The binding 
reaction was filtered under vacuum on Durapore filters (GVWP 02500,0.22 Jim, Millipore) or 
GF/C glass microfibre filters (Whatman). The filters were washed 5 times with 10 ml of cold 
Tris-HCL, pH 7.6. The filters were dried 1 h at RT, 5 ml of Scintiverse BD cocktail (Fisher) 
was added and the 125Iodine counts were measured using a Liquid Scintillation Analyzer 
(Packard 1900TR). 
Mannose 6-phosphate detection on glycoproteins by overlay assay 
Detection of mannose 6-phosphate on glycoproteins was done according to Valenzano 
et al. (32). The samples were diluted in 2 x SDS-PAGE sample buffer without (3-
mercaptoethanol and heated at 50 °C for 10 min. The samples were electrophoresed on a 
12.5 % acrylamide gel at 35 mA for 3 h in 0.4 M glycine, 50 mM Tris, 1 % SDS, pH 8.35. The 
molecular weight markers, bovine serum albumin (66 kDa), ovalbumin (45 kDa), carbonic 
anhydrase (30 kDa), myoglobin (18 kDa), cytochrome c (12.5 kDa), were treated like the 
above samples. The separated proteins were transferred onto nitrocellulose membrane 
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(Nitrobind 0.45 |lm, Osmonics) using a Hoefer TE50 apparatus at 30 V for 12 h at 4 °C in 
transfer buffer (25 mM Tris, 190 mM glycine, 20 % methanol, pH 8.3). The membrane was air 
dried and baked in a vacuum oven for 2 h at 80 °C. The membrane was then stained with 
0.2 % Ponceau S in 3 % trichloroacetic acid to ascertain uniform transfer of proteins to the 
membrane. After destaining with water, the membrane was blocked for 1 h by rocking at 4 °C 
in blocking buffer (137 mM NaCl, 2.7 mM KC1, 10.1 mM Na^HPO* 1.76 mM KH2P04, 
0.2 % Tween 20, 10 mg/ml BSA, 5 mM Na ^-glycerophosphate pH 7.2). The blocking buffer 
was replaced with fresh blocking buffer containing 0.4 ng/ml I25I-IGFII/M6P receptor and 
rocked at 4 °C for 8 h. For the blots performed in the presence of competitors, the labeled 125I-
IGFH/M6P receptor was pre-incubated in blocking buffer containing mannose 6-phosphate 
(10 mM) or r-IGFH (0.75 |ig/ml), at 4 °C for 1 hour. Nonspecific binding to the membrane 
was removed by washing the blots 10 times (30 s each) with 137 mM NaCl, 2.7 mM KC1, 
10.1 mM Na2HP04,1.76 mM KH2P04,0.2 % Tween 20, pH 7.2. The membranes were dried, 
wrapped in Saran Wrap and exposed to a Phosphorlmager screen and scanned using a 
Molecular Dynamics Phosphorlmager 400A. 
RESULTS: 
The wet weight and DNA content of the uterus correlate with the presence of MRP/PLFs 
MRP/PLFs are thought to be growth factors for mid-gestational uterine cells because 
of their ability to stimulate DNA synthesis in primary uterine cell cultures (4). The profiles of 
the wet weight and DNA content of whole uteri were measured during gestation to better 
understand the biology of the mouse uterus and to establish a possible correlation with 
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MRP/PLF expression. Mouse uteri were dissected from pregnant female at different days of 
gestation and weighed. A two-fold increase in the uterus wet weight from day 0 to day 8 was 
observed, followed by a 4-fold increase from day 8 to day 14. From day 14 to day 16, the wet 
weight of the uterus stabilized followed by a further increase of 1.4-fold until parturition 
(Figure 1 A). Figure IB displays the profile of total DNA per uterus during gestation and 
demonstrates that the change in total DNA paralleled the profile of the uterus wet weight. 
Prior to day 8, the amount of DNA per uterus did not increase significantly, but from day 9 to 
day 14 the amount of DNA increased by nearly 3-fold. After day 14, there was no significant 
increase in the total DNA in the uterus until birth whereas the wet weight of the uterus still 
increased. Uterine total DNA content increased between days 9 and 14 by 0.2 }lg DNA/ 
uterus/day, which corresponds to an increase of 15 % of the uterine mass per day. An overlay 
of the expression profile of MRP/PLF proteins during gestation reveals a positive correlation 
between the rapid increase in both wet weight and DNA amounts and the peak of MRP/PLF 
secreted by the placenta (Figure 1 A&B). 
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Figure 1: Wet weight and total DNA in the mouse uterus during gestation. 
In panel A and B, the hatched line (—) represents the expression profile of MRP/PLFs proteins in the placenta. 
Panel A: the number of uteri collected at different days of gestation and weighed was: 1 (day 2), 3 (day 6), 4 (day 
4), 5 (days 1,3,8, 10,12,14), 6 (days 5,7, 16), 10 (day 17), 11 (days 15), 12 (day 9), 17 (day 13), 26 (day 0), 59 
(day 11). Panel B: the amount of DNA per uteri was determined as described in Materials and Methods. The 
number of uteri for each day was: 2 (days 1,4,5,6,7,8, 10), 3 (days 0, 12), 4 (days 11,14, 16, 18, 19), 5 (day 
17), 6 (days 9,15, 17), 7 (day 13).The error bars represent +/- 1 standard deviation. 
Estradiol-17ft and progesterone profiles in placenta, uterus and plasma during gestation 
In sub-confluent BN/L liver cells, the level of mrp/plf mRNA increased upon addition 
of estradiol-17p, suggesting a possible regulation of MRP/PLF expression by steroids (16). 
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However, the reported plasma levels of estradiol-1?P in the plasma (17) do not correlate with 
the rapid increase in MRP/PLF mRNA, at gestational day 10 to 14, in the placenta (18). The 
collective sum of many studies investigating the factors regulating uterine growth in immature 
or ovariectomized mature female rats and mice have shown that estrogen and progesterone are 
major regulatory factors (10, 33-35). MRP/PLF could be regulated by steroids expressed 
locally in the uterus or the placenta. However, no data on the local concentrations of estradiol-
1?P and progesterone was available for these tissues during gestation. Therefore, the 
concentrations of estradiol-1?P and progesterone were measured by RIA in the uterus and 
placenta of CF-1 mice at various stages of gestation. 
Figure 2A shows that the levels of estradiol-1 ?P in the uterus and the placenta were 
less than 1 pg/mg throughout gestation except for 2 distinct peaks, one at day 6 (71.2 ± 27.3 
and 197.3 ± 36.7 pg/mg in the uterus and the placenta, respectively) and the other at day 14 of 
gestation (33.8 ± 9.0 and 45.2 ± 12.9 pg/mg in the uterus and placenta, respectively). The 
concentration of estradiol-1?P in the plasma was highest in day 0 pregnant mice (49.2 ± 
2.9 pg/ml) and decreased to 20 pg/ml until day 14 when the plasma level steadily increased to 
55.6 pg/ml at day 18. 
The levels of progesterone were also measured in the same tissues. Figure 2B shows that 
the progesterone levels in the placenta and the uterus were approximately 50 pg/mg for both 
tissues during gestation except for a peak on day 10 of gestation (427.0 ± 94.5, 
142.4 ± 27.4 pg/mg in the placenta and uterus respectively). In the plasma, low levels of 
progesterone on day 0 (4.9 ± 0.2 ng/ml) initially peaked on day 8 (27.0 ± 3.2 ng/ml) and then 
decreased to day 10 levels (19.3 ± 0.6 ng/ml). The concentration increased to its maximum on 
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day 12 (42.1 ± 6.3) followed by a decrease to day 18 (27.34 ± 1.7 ng/ml). Both gestational 
profiles for estradiol-17P and progesterone in the plasma of the CF1 mice were similar to the 
ones previously reported for Swiss mice (17). 
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Figure 2: Estradiol 1?P and progesterone levels in the uterus, placenta and scrum during gestation. 
The levels of estradiol during gestation (panel A) were measured by RIA in the uterus (#), the placenta(A) and 
plasma (•) as described in Materials and Methods. The levels of progesterone were measured by RIA in the same 
tissues during gestation (panel B). For both panels, the number of samples contributing to each average value was 
as follows: 2 (days 0,6, 10,18), 3 (days 8,12, 14, 16). 
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Effect of estradiol-17/? and progesterone on MRP/PLF s production by the placenta 
The peak of progesterone observed in the placenta and the uterus on day 10 suggested 
that progesterone could be involved in up-regulating the secretion of MRP/PLFs by the 
placenta. To examine whether progesterone could in fact stimulate the secretion of MRP/PLPs 
from the placenta, day 8 and 9 minced placental tissue cultures were treated with 10 * to 
10 * M progesterone. These concentrations were similar to the ones measured for the placenta 
in Figure 2B. Secreted MRP/PLFs were detected in the placental tissue cultures after 24 h by 
Western blot of conditioned medium (Figure 3). There was no observed increased in 
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Figure 3: Western Mot of conditioned medium of placental minces stimulated with steroids. 
Western blot showing MRP/PLFs present in the conditioned medium of minced placental cultures (day 9 of 
gestation; day 8 not shown) treated with 0,10"6,10"7 or 10"* M of progesterone. Each concentration was tested in 
triplicate (a, b, c) and the same volume of conditioned medium was used to detect MRP/PLFs on Western blot. 
The molecular weight markers used are defined in Materials and Methods. 
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MRP/PLF accumulation in the conditioned medium of day 8 or 9 minced placental tissue 
cultures after progesterone treatment. Additionally, Estradiol-170 did not have any effect on 
the secretion of MRP/PLFs in the conditioned medium of day 8 and 9 minced placental tissue 
cultures (data not shown). 
3H-thymidine incorporation of uterine cells stimulated by MRP/PLFs 
Different preparations of purified MRP/PLFs were tested for binding to the MRP/PLF 
uterine receptor in vivo (uterine primary cell cultures and minced uterine organ cultures) to 
define the conditions for MRP/PLF mediated signaling. These MRP/PLF preparations were 
tested for their ability to stimulate 3H-thymidine incorporation of gestational day 11, uterine 
primary cell cultures isolated using the two different methods described in Materials and 
Methods. One MRP/PLF preparation was isolated from conditioned medium of FGF-
stimulated Swiss 3T3 cells (36). Another preparation was isolated from the conditioned 
medium of FGF-stimulated BALB/c normal liver (BN/L) cells (4). Finally, two different 
preparations were isolated from the conditioned medium of stably transfected 293 cell clones 
secreting recombinant His-PLFl (Chapter 2). No reproducible increase in thymidine 
incorporation could be demonstrated in uterine primary cell cultures (isolated with either 
method) treated with MRP/PLFs isolated from 3T3 or BN/L cells nor with His-PLFl isolated 
from transfected 293 cells (data not shown). 
MRP/PLFs isolated from BN/L cells were previously shown to stimulate 3H-thymidine 
incorporation in gestational day 11 minced uterine tissue cultures (Rosenzweig, unpublished 
data). Unlike isolated primary uterine stromal cell cultures, minced uterine tissue cultures 
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contain multiple cell populations that might respond to MRP/PLF-stimulation and show 
increased thymidine incorporation. Therefore, MRP/PLF preparations isolated from 3T3, 
BN/L cells and recombinant His-PLFl and MRP3 were re-tested on minced uterine tissue 
cultures. Figure 4 shows the absence of a reproducible increase in thymidine incorporation by 
gestational day 11 minced uterine tissue cultures treated with different concentrations of 
recombinant MRP3 (without histidine tag). Similarly, no MRP/PLF preparations from 3T3 or 
BN/L cells tested stimulated 3H-thymidine incorporation in day 11 minced uterine tissue 
cultures. 
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Figure 4: 3H-Thymidine Incorporation of day 11 minced uterus tissue cultures treated with MRP3. 
Minced uterine tissue cultures were treated with different concentrations of recombinant MRP3 (without a 
histidine tag) for 30 h in the presence of 8 liCi/ml ^-thymidine. The amount of radioactivity in each piece of 
uterus was normalized to the dry wet of the tissue. DNA synthesis is expressed as fold over control (cpm 
treatment / cpm control). The error bars represent the standard deviation of four replicates. 
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In vitro membrane binding assays to the MRP/PLF receptors 
To examine if His-MRP3 purified in Chapter 2 could bind to the putative MRP/PLF 
uterine receptor, His-MRP3 was iodinated and tested for binding to gestational day 11 uterine 
membrane preparations under the conditions reported by Nelson et al. (4). In that report, 
1 mM Mannose 6-phosphate did not compete with the 125I-MRP/PLF for binding to these 
membrane preparations indicating that the binding activity was not due to the IGFH/M6P 
characterized for maternal liver (4). For the following experiments, several concentrations of 
His-MRP3 or MRP3 (Chapter 2), and gestational day 11 uterine membranes were used to fall 
within the range of concentrations previously reported to show binding activity. Binding of 
l25I-His-MRP3 to gestational day 11 uterine membranes was detected in the presence of 10 
mM mannose 6-phosphate but competition with non-labeled His-MRP3 did not decrease the 
number of counts suggesting non-specific binding to the uterine membranes or to the 
Durapore filters used in that assay. Similarly, only non-specific binding was observed when 
125I-MRP3 (without the histidine tag) was tested on gestational day 11 uterine membrane 
preparations (data not shown). 
Binding to the IGFD/M6P receptor was used to determine the glycosylation state of 
His-MRP3 and MRP3. There is only a two amino acid difference between PLF1 and MRP3 
which does not affect the number of putative N-glycosylation sites present on MRP3. The 
amount of glycosylation of His-MRP3, determined by the estimation of the molecular weight 
determined by SDS-PAGE, was similar to wild type MRP/PLF (Chapter 2). Binding of His-
MRP3 to the IGFD/M6P receptor present in day 16 pregnant maternal liver membrane 
preparation was performed according to Lee and Nathans (23). First, the integrity of the 
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gestational day 16 maternal liver membrane preparation was verified using labeled insulin 
growth factor II (IGFII) which also binds to the IGFD/M6P receptor via a different binding site 
(37). Figure 5 shows that under the experimental conditions reported by Lee and Nathans (23) 
l25I-IGF-n can bind to gestational day 16 maternal liver membranes. The addition of 100 fold 
cold IGF-II partially competed the binding of the labeled IGF-II to the membranes. Moreover, 
although the GF/C filters gave higher background counts, compared to the Durapore filters, 
the GF/C filters also showed a greater difference between binding of 125I-IGF-II plus or minus 
cold IGF-II. 
His-MRP3 (Figure 5) and MRP3 (data not shown) non-specific binding to gestational 
day 16 maternal liver membrane preparations was detected using GF/C or Durapore filters. 
Several concentrations of His-MRP3 or MRP3 and gestational day 16 liver membranes were 
used and were within the range of concentrations reported by Lee and Nathans (23). 
Overlay assay to detect mannose 6-phosphate on His-MRP3 
The absence of binding of His-MRP3 to the day 16 liver membranes suggested the 
possibility that recombinant His-MRP3 isolated from 293 cells did not have mannose 6-
phosphate. The overlay assay developed by Vaienzano et al. (32) showed that the bovine 
IGFH/M6P receptor can bind to His-MRP3 (Figure 6 A). Receptor binding by His-MRP3 was 
competed off by the presence of mannose 6-phosphate in the overlay solution (Figure 6 B). 
Duplicate samples for the overlay assay were used on a Western Blot to ascertain the presence 
of the His-MRP3 (Figure 6 C). Unexpectedly, two bands were present, one at approximately 
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Figure 5: Receptor binding assay on gestational day 16 maternal liver membrane vesicles 
Gestational day 16 liver membrane receptor binding assay was outlined in Materials and Methods. In a final 
volume of 0.5 ml, 12 |lg of the membrane preparations and ligand 125I-IGF-II (IGFII)and l25I-His-MRP3 
(MRP3) were incubated with or without competitor, IGF-II (IGFII), Mannose 6-phosphate (M6P), His-MRP3 
(MRP3) at 4 °C overnight. The mixture was filtered under vacuum using Whatman GF/C filters (glass fiber) or 
Millipore Durapore GVWP filters (PVDF) and washed 5 times with 10 ml of 25 mM Tris, HC1, pH 7.6. The 
cpm retained by the filters are represented as total cpm retained (grey bars) or as % of retained cpm over total 
cpm (striped bars). The filters used were G: Whatman GF/C, D: Millipore Durapore GVWP). Each condition 
was repeated in triplicate, and the error bars represent +/-1 standard deviation. 
35 kDa and the other one approximately 50 kDa. The higher molecular weight band appears 
to be very poorly detected by the IGFH/M6P receptor. Figure 6 D showed that the presence 
of the high molecular weight band for His-MRP3 in the Western blot is due to the absence of 
P-mercaptoethanol. These results suggest that at least 50 % of the His-MRP3 isolated 
contained detectable amounts of mannose 6-phosphate. Recombinant-IGF-H was also used as 
a control, and binding of the receptor was detected and competed off by the presence of 
r-IGF-II (data not shown). 
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IGFXX/M6P Overlay assay Western Blot 
IGFII/M6P receptor IGFII/M6P receptor 
+ 10 mM M6P 
Figure 6: Overlay assay showing the presence of mannose 6-phosphate on His-MRP3 
The different fractions from the purification scheme used in Chapter 2 were tested for the presence of mannose 6-
phosphate using the overlay assay as described in Materials and Methods. In panels A, B and C Lane 1: 
Conditioned medium before ultrafiltration. Lane 2: Concentrated medium before loading on the primary nickel 
column. Lane 3: Pooled fractions containing His-MRP3 post-first nickel column and pre-iectin column. Lane 4: 
Pooled fractions containing His-MRP3 post-lectin column and pre-secondary nickel column. Lane 5: Pooled 
fractions containing His-MRP3 after the second nickel column. Duplicates of the different fractions were loaded 
at equal volumes on 12.5 % SDS-PAGE. Panel A shows the overlay assay using ,25I-IGFII/M6P receptor, panel B 
shows the overlay assay using l2SI-IGFII/M6P receptor pre incubated with 10 mM mannose 6-phosphate. Panel C 
shows the Western blot using antiserum 89Rbl3b raised against MRP/PLFs. Panel D shows a Western blot of the 
pooled fractions containing His-MRP3 after the second nickel column resuspended in 2 x loading buffer with or 
without P-mercaptoethanol (+BME, -BME respectively) before heating the samples at 50 °C and loading them 
on 12.5 % acrylamide gel. The numbers on the side indicates the molecular weight in kDa of protein standards 
defined in Materials and Methods. 
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Detection of MRP/PLF mRNA in embryonic spine 
Dudley reported the detection of mrp/plf mRNA in gestational day 11 embryonic tail 
and in gestational day 17 embryonic spines by Northern blot and RT-PCR (24). However, 
Jackson et al. showed that although recombinant PLF1 could bind to the embryonic spine 
using l25I-labeled PLF1 and successfully competed it off using 10 mM mannose 6-phosphate, 
the MRP/PLF mRNA could not be detected using in situ hybridization on mid-sagittal 
sections of gestational day 16 embryos or RT-PCR on gestational day 16 embryonic spine 
RNA preparation (25). To determine the expression time course and isoform of mrp/plf 
mRNA expressed in the embryonic spine from day 13 to day 19 of gestation, RT-PCR and 
Northern blot analysis were performed. No mrp/plf mRNA was detected by Northern blot on 
total RNA isolated from whole embryos aged from day 9 to day 19 of gestation (data not 
shown). Nor was mrp/plf mRNA detected by RT-PCR in the spine, tail, skin, heart or ribs 
collected from gestational day 18 embryos. However, a positive control made of day 11 
placenta total RNA showed that mrp/plf mRNA was detectable by both methods. In addition, 
GPDH mRNA used as a loading control for the Northern blot and as a positive control for the 
RT-PCR showed that the total RNA isolated contained intact mRNAs (data not shown). 
DISCUSSION: 
Examination of uterus weight and total DNA both showed a rapid increase from day 9 
to 14. These two events correlate to the time when the uterus undergoes decidualization 
which is characterized by uterine stromal cell proliferation and differentiation as well as a 
massive infiltration of leukocytes (19, 20) and increased vascular permeability (21). The 
78 
combination of these four events can account for the rapid increase in uterine wet weight 
observed from gestational day 9 to 14. Differentiating stromal cells replicating their DNA 
without cell division (enderoreplication), cell proliferation of other stromal cells, and 
leukocyte infiltration can all account for the rapid increase in uterine DNA. During gestation, 
the decidua is degraded to make room for the growing embryo. Up to day 14, the embryo wet 
weight increases very slowly, which is paralleled by a slow degradation of the decidua (38). 
The decidual degradation, accomplished by slow resorption of the decidual cells, accentuates 
the rapid increase in uterine wet weight and DNA amounts. 
From day 14 to birth, DNA content in the uterus does not increase significantly 
whereas the uterine wet weight still increases. Interestingly, during this period the decidua is 
rapidly degraded to accommodate the now rapidly growing embryo (38, 39). The increase in 
wet weight without apparent increase in DNA synthesis suggests that during late gestation 
there is a combination of increase in uterine cell size (hyperplasia) and increase in protein 
accumulation or retention of water by the uterus. From day 14 to day 16 there is no increase in 
wet weight. This would account for the switch between the end of the decidual regression and 
the DNA synthesis-independent increase in wet weight of the uterus. 
The plasma profiles of both estradiol-17(3 and progesterone measured here are very 
similar to the one obtained by McConnack and Greenwald (17). Estradiol-17(5 is present in 
the uterus and the placenta, and peaks on two days. Gestational day 6 is the highest with the 
smallest peak at gestational day 14. The uterus and placenta possess the enzymes necessary for 
estradiol-17P synthesis (40,41) suggesting that these tissues can synthesize estradiol-17p. 
However, it can not be ruled out that the high levels detected at gestational day 6 and the late 
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peak at gestational day 14 are due to the accumulation of estradiol-17P in the placenta and the 
uterus rather than de novo synthesis. Furthermore, the significance of the high levels of 
estradiol-17p in the placenta and uterus at day 6 is not known. The peak observed at day 14 
correlates with rapid embryo growth and rapid cell death in the decidua. The biology of the 
decidua and the placenta during this time in pregnancy is not well studied. Therefore it is 
difficult to speculate on the relevance and the role for the presence of estradiol-1?P in the 
uterus and the placenta at day 14. 
In the placenta and the uterus the levels of progesterone are low at the beginning of 
gestation and peak at day 10 to rapidly decrease to their minimum after day 14. In the 
placenta, all the enzymes needed for progesterone synthesis from cholesterol are present in the 
trophoblastic giant cells and their gene expression patterns during gestation are identical to the 
pattern of progesterone accumulation in the placenta (41). In addition, progesterone secretion 
in cultured mouse trophoblast cells of different gestational ages, showed a profile of 
expression identical to the one observed for the whole placenta (42). Progesterone has been 
shown to decrease mouse placental lactogen I (mPL-I) expression in placental mixed primary 
cell cultures (43). The luteotropic action of mPL-I is thought to be replaced in late gestation by 
mouse placental lactogen II (mPL-II) which starts to be detected in the circulation in mid-
gestation, and stays at high concentration throughout the rest of gestation. Progesterone could 
be involved in this switch by lowering the amounts of mPL-I and increasing the amounts of 
mPL-II. The reason for the switch in the mPL is unclear as the same trophoblastic giant cells 
secrete both placental lactogens (44). 
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Unlike the effect of progesterone on mPL-I and mPL-II secretion, progesterone had no 
effect on the accumulation of MRP/PLFs in the conditioned medium of minced placental 
tissue cultures from day 9 of gestation. Similarly, estradiol- 17p did not change the 
accumulation of MRP/PLFs in the conditioned medium of the minced placental tissue cultures 
from day 9 of gestation. At day 14 of gestation, the decrease of MRP/PLF expression is 
accentuated, which correlates with the presence of estradiol-170 in the uterus and the placenta 
at day 14. Estradiol-17P could play a role in down regulation MRP/PLF expression in the 
placenta, similarly to the action of progesterone on mPL-I around day 10 of gestation. 
The day 11 minced uterine organ culture and uterine primary cell cultures were used to 
determine if the recombinant His-MRP/PLFs could stimulate DNA synthesis through the 
uterine receptor in vivo. His-PLFl did not stimulate 3H-thymidine incorporation in the day 11 
minced uterine organ cultures. A similar experiment was done with MRP3 after enterokinase 
removal of the histidine tag and no increase in 3H-thymidine incorporation was observed in the 
day 11 uterine organ cultures. His-PLFl, His-MRP3 were tested on day 11 uterine primary 
cell cultures prepared using both methods described in Materials and Methods. No significant 
3H-thymidine incorporation was detected after stimulation of the cells isolated by either 
method with the different recombinant MRP/PLFs. One conclusion from these experiments is 
that recombinant MRP/PLF isolated from the conditioned medium of stably transfected 293 
cell could not bind to the uterine cell receptors. Another conclusion is that in 293 cells the 
isolated recombinant MRP/PLFs were biologically active, but the minced uterine organ 
cultures or the primary uterine cell cultures could not give the previously detected 
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3H-thymidine incorporation because the cultures behaved differently in this study (Nilsen-
Hamilton unpublished data and (4)). 
To avoid the variables introduced by cell culture, the day 11 uterine membrane binding 
assay (4) was used to test the binding of His-MRP3 and MRP3, with the histidine tag 
removed, to the uterine MRP/PLF receptor. No specific binding of 125I-His MRP3 or I25I-
MRP3 was detected on day 11 uterine membranes. This suggests that the 293 cell recombinant 
MRP3, with or without histidine tag, does not bind to the uterine receptor. Recombinant PLF1 
from CHO cells was shown to bind to the IGFII/M6P receptor present on day 16 maternal 
liver membranes (23). When tested, l25I-His MRP3 or I25I-MRP3 did not bind specifically to 
the day 16 liver membrane via the IGFB/M6P. However, r-IGF-II bound specifically to day 16 
liver membrane suggesting that the IGFH/M6P was present on the day 16 liver membrane 
tested and that the binding assay was performed properly. 
In the receptor binding assay, it was found that the type of filters used to separate the 
bound radioactive proteins from the free form is important. The glass fibers filters from 
Whatman, used by Lee et al. (23), retained more radioactivity compared to the PVDF filters 
from Millipore, used by Nelson et al. (4), suggesting that more membrane vesicles were 
retained which ultimately led to better differentiation between experimental conditions. 
The glycosylation patterns of MRP/PLFs could have a serious impact on the binding 
activity of MRP/PLFs to their receptors. Analyses of the glycosyl groups on recombinant 
glycoproteins expressed by CHO cells, 293 cells and SF9 insect cells, showed that these cells 
secreted glycoproteins with different sugar residue composition (45,46). Using the overlay 
assay developed by Valenzano et al. (32), at least 50 % of the His-MRP3 isolated from 
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293 cells had mannose 6-phosphate present. Interestingly, the His-MRP3 that did not bind the 
IGFD/M6P receptor in the overlay assay had a slower relative migration on the non-reducing 
SDS page. This slower migrating band disappears when P-mercaptoethanol is added 
suggesting that the three possible disulfide bridges present in native MRP/PLF changes the 
conformation of MRP/PLF to allow different migrating characteristics in the reducing SDS-
PAGE. Migration could be independent of the tertiary structure but relies on the differences in 
charges produced by the absence of mannose 6-phosphate, or the presence of other sugars. 
The presence of MRP/PLF in the embryo was further investigated to determine if the 
MRP/PLF protein detected in the spine and heart structures of day 10 to day 18 embryo 
endothelial cells by binding to the M6P/IGFII receptor and by immunohistochemistry (25) was 
due to localized synthesis or export from the placenta. Dudley reported the presence of 
mrp/plf mRNA by RT-PCR and Northern blot analysis in day 11 heart and tail as well as 
gestational day 17 embryonic skin, heart, spine, rib (24). Northern blots performed on whole 
embryos from gestational day 9 to day 19 did not detect mrp/plf mRNA except for a very light 
band in day 10 embryo which is likely to be due to placental tissue contamination during the 
dissection procedure. In effect, the embryo is very small and looks very similar to placental 
tissue and day 10 placenta has the highest amount of mrp/plf mRNA during all of gestation. 
Day 11 embryos which are easier to separate from the placenta did not show any mrp/plf 
mRNA. RT-PCR and Northern blot performed on day 18 embryonic tissues (skin, heart, 
spine, rib, tail) as well as isolated embryonic spines (day 13 to day 19 of gestation) did not 
show the presence of any mrp/plf mRNA. These results support the data published by Jackson 
and Linzer (25) showing that no mrp/plf mRNA could be detected by in situ hybridization and 
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RT-PCR in the spines and hearts of embryos. This leads to the conclusion that the only known 
cells secreting MRP/PLFs are the placental trophoblastic giant cells (1) and keratinocytes (47). 
The binding of MRP/PLF to the embryo parallels the localization of the IGFD/M6P receptor in 
the embryo (48) suggesting that the role played by MRP/PLF in the embryo is via the 
IGFII/M6P receptor. 
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CHAPTER 4. 
EXPRESSION OF 24P3/UTEROCALIN, A LIPOCALIN FAMILY 
MEMBER, IN THE EMBRYO, JUVENILE AND ADULT MICE 
ABSTRACT: 
The secreted protein, 24p3/uterocalin is one of several proteins superinduced upon the 
stimulation of quiescent 3T3 cells with fibroblast growth factor. Expression of 24p3/uterocalin 
was detected in the embryonic spine on gestational day 13, shown to increase throughout 
gestation and continued to increase over the life time of the mouse. In the liver 
24p3/uterocalin mRNA levels were the highest in the late-gestational fetal liver and decreased 
within the first week after birth. The 24p3/uterocalin mRNA was also detected in the spleen of 
juvenile adults. Several types of tissue undergoing remodeling show an increase in 
24p3/uterocalin suggesting a role in tissue remodeling. The presence of 24p3/uterocalin 
mRNA in the fetal and juvenile liver and in the spine after birth appeared to correlate with 
hematopoiesis in these tissues and therefore it is hypothesized that 24p3/uterocalin may have a 
potential role in events related to both embryonic and adult hematopoiesis. 
INTRODUCTION: 
Mitogens such as fibroblast growth factor (FGF), epidermal growth factor (EGF) or 
serum, stimulate the secretion of several proteins in cell culture. One of these proteins is 
mitogen regulated protein/proliferin (MRP/PLF) whose secretion from quiescent 3T3 cells is 
induced 20 hours after the addition of any of the mitogens mentioned above (1). Similarly, 
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SIP24 was identified as a protein secreted after FGF treatment of quiescent mouse 3T3 cells. 
This SIP24 induction in response to mitogen stimulation occurred within 10 hours of FGF 
addition to these 3T3 cells. Addition of the protein synthesis inhibitor cycloheximide with the 
FGF increased SIP24 accumulation 4 to 5 fold in the conditioned medium of quiescent 3T3 
cells. Unlike SIP24, MRP/PLF was not superinduced by the addition of cycloheximide with 
FGF. This observation suggests that although MRP/PLF and SIP24 can both be stimulated by 
FGF, their synthesis and secretion appear to be regulated differently (2). 
The mRNA 24p3 was up-regulated in mouse primary kidney cell cultures infected with 
the polyoma or SV40 viruses (3). The 24p3 protein was also found to be a major secreted 
protein when PU5.1.8 macrophage cells were stimulated with LPS (4). Protein sequencing of 
peptides obtained from enzymatic digestion of SIP24 revealed that it was identical to the 24p3 
protein (5). Careful analysis of the amino acid sequence of 24p3 revealed that it belonged to 
the growing superfamily of lipocalins (6,7). The lipocalin family is characterized by a low 
amino acid alignment (less than 20 %), but a high degree of conservation in 3 domains and a 
common folding pattern. The so-called lipocalin fold is a hydrophobic cavity formed by 8 
antiparallel ^-sheets allowing the binding of hydrophobic molecules such as retinoids, fatty 
acids, and steroids (8). 
Studies on the regulation of the 24p3 gene expression led to the cloning of the 24p3 
promoter and gene. Two, overlapping, glucocorticoid response element consensus sequences 
were found on this promoter suggesting a possible regulation by glucocorticoids (9). 
Subsequently, addition of the glucocorticoid, dexamethasone, to mouse embryonic fibroblast 
L cells was shown to increase the mRNA, as well as levels of secreted 24p3 protein levels (9). 
Concurrently, Liu et al. showed that the addition of dexamethasone with cycloheximide to 
mouse 3T3 and BNL (embryonic liver) cells, increased 24p3 protein levels (5). Injection of 
dexamethasone in both male and female adult mouse triggered the accumulation of 24p3 
mRNA in the liver. In addition, during acute phase response triggered by turpentine injection, 
24p3 mRNA levels increased in the mouse liver as well as in the uterus. This led to the 
conclusion that 24p3 was a new, positive acute phase, response protein (5). 
During pregnancy, the uterus at gestational day 11 contains detectable amounts of 
24p3 mRNA (5). At birth, mRNA levels of 24p3 increase in the uterus to be 16 fold higher the 
day after birth than in the non-pregnant uterus. The levels then decrease rapidly 2 to 3 days 
after birth as the uterus undergoes regression (10, 11). The 24p3 protein levels in the uterus 
follow closely the pattern of expression of 24p3, and in situ immunohistochemistry suggested 
that 24p3 was located in the luminal and glandular epithelium. The high expression levels of 
the lipocalin 24p3 in the uterus led to the renaming of 24p3 as uterocalin (11). 
Upon injection of the estrogen analogue, diethylstilbesterol, 24p3/uterocalin secretion 
in the uterine luminal fluid was stimulated in immature female mice (12). A more detailed 
analysis in mature mice revealed that 24p3/uterocalin mRNA and protein was expressed at 
high levels before ovulation, when high amounts of estradiol are present in the plasma. After 
ovulation, progesterone increases and the amounts of 24p3 mRNA and protein were shown to 
decrease. This ovarian steroid model could be replicated in immature female mice injected 
with estradiol and/or progesterone. These observations suggested that 24p3/uterocalin could 
be regulated directly or indirectly by ovarian steroids (13). 
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Two surveys of the tissue specific expression patterns for 24p3/uterocalin revealed 
expression in several organs. Chu et al. looked in 42 to 56 day-old male and female mice and 
found mRNA expression in the lung, spleen, vagina and epididymis. Other tissues like the 
brain, thymus, heart, liver, kidney, pancreas, ovary, testis, prostate did not express detectable 
levels of 24p3/uterocalin mRNA (12). Garay-Rojas et al. using younger, 21 day-old male mice 
found 24p3/uterocalin mRNA expression in the lung, spleen, testis, and liver. Tissues studied 
that did not express detectable levels of mRNA were brain, thymus, kidney and muscle. 
Further study of 24p3/uterocalin expression in day 10 mice revealed that in the liver, spleen 
and kidney the mRNA was expressed at higher levels compared to 21-day old mice. The 
24p3/uterocalin mRNA levels decreased to undetectable levels in the kidney by day 25 and in 
the spleen and liver at 45 to 65 days, respectively (9). 
Interestingly, in vitro studies on the effect of interleukin-3 (IL-3) deprivation on the 
mouse leukocytic cell line FL5.12 demonstrated an upregulation of 24p3/uterocalin mRNA 
and protein secretion in FL5.12 cells undergoing apoptosis in response to the removal of IL-3. 
These studies showed that the secreted 24p3/uterocaiin triggered apoptosis via an autocrine 
regulatory loop (14). 
Additional proposed functions for 24p3/uterocalin include involvement in tissue 
remodeling. After weaning, the mammary gland undergoes involution which is accompanied 
by rapid tissue resorption. The expression profile in the mammary gland of 24p3/uterocalin 
mRNA and protein correlates with the regression of this tissue (15). Also, during 
endochondral bone formation, chondrocyte differentiation is accompanied by upregulation of 
the chicken and rat homologues of 24p3/uterocalin (16). The 24p3/uterocalin human 
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homolog, Neutrophil gelatinase-associated lipocalin (NGAL), is expressed by leukocytic cells 
in the bone marrow and in particular by the neutrophils (17). The survey of several human 
tissues showed varied expression in tissues like the bone marrow, thymus, liver, fetal spleen, 
mammary gland, trachea, lung, spleen (18). No definitive role for 24p3/uterocalin and its 
homologs in the human, rat and chicken can be deduced from this varied expression pattern 
throughout the body. 
Many putative functions have been proposed for 24p3/uterocalin and homologs, yet no 
specific roles have been clearly defined. To provide additional insight into the function of 
24p3/uterocalin, a study of its mRNA expression in liver, spleen and spine during mouse 
embryogenesis was undertaken. 
MATERIALS AND METHODS: 
Animals and reagents 
Female CF1 mice, originally obtained fron? Charles River Laboratories, Inc., were 
maintained as a breeding colony for the Nilsen-Hamilton laboratory in one of the Iowa State 
University animal facilities, with a 12 h light, 12 h dark cycle and food and water ad libitum. 
All animals were housed and treated according to current NIH guidelines. The research 
reported here was conducted in accordance with the standards set forth in the NIH Guide for 
the Care and Use of Laboratory Animals. Prior approval was obtained from the Iowa State 
University Committee on Animal Care for all procedures performed on the animals used in 
these studies. Animals were killed by cervical dislocation or C02 asphyxiation before removal 
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of tissues for the described studies. The detection of a copulation plug or sperm in the vaginal 
smear was used to determine day 0 of gestation. 
RNA isolation. Northern Bloting and RT-PCR 
Total RNA was isolated from 50 to 100 mg of frozen tissue using TRIzol® reagent 
(Gibco, Invitrogen Corporation) and resuspended in RNAse free water. Total RNA, 15 to 
30 |ig determined by absorption at 260 nm, was dried using a vacuum centrifuge (SpeedVac, 
Savant) and the pellet was resuspended in 15 111 of RNA loading buffer (48 % formamide, 
0.11 M MOPS, 6.4 % formaldehyde, 5.3 % glycerol, 0.25 % bromophenol blue). The samples 
were boiled 2 min and loaded onto a 1 % agarose gel, containing 1.7 % formaldehyde, 
0.5 lig/ml ethidium bromide. Electrophoretic separation was completed at 60 V for 3 h in 
0.2 M MOPS, 50 mM sodium acetate, 10 mM EDTA pH 7.0. The gel was rinsed at room 
temperature 15 min in deionized water followed by 15 min in 50 mM NaOH. The RNA was 
transferred to Zeta-Probe® GT Blotting membrane (Bio-Rad) by alkaline capillary transfer 
overnight in 50 mM NaOH. The membrane was washed 10 min with 2X SSC (1 X SSC: 
0.15 M NaCl, 15 mM sodium citrate pH 7.0) and baked 15 min at 80 °C under vacuum. Before 
probing, the membrane was pre-hybridized at 47 °C for 6 h with 100 |ig/ml yeast tRNA and 
salmon sperm DNA, boiled 2 min and chilled on ice, in 0.6 M NaCl, 40 mM NaH2P04, 
50 mM EDTA, 7 % SDS, 1 % PEG 20000,40 % formamide, 0.1 % NP40, pH 7.4. A 32P-
labeled 24p3/uterocalin probe was generated by using the Multiprime DNA labeling system 
(Amersham Pharmacia), 24p3/uterocalin cDNA and 3000Ci/mmol a-32P-dCTP (ICN). 
Unincorporated dNTPs were separated from the labeled probe by gel filtration using a 
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micro bio-spin® P-30 Tris chromatography column (Bio-Rad). The probe in 10 mM Tris pH 
7.4 was boiled 5 min and chilled on ice before adding to the blot in the pre-hybridization 
solution for a 16 h incubation at 47 °C. The membrane was washed twice for 15 min with 
0.5X SSC, 0.1 % SDS at room temperature followed by 2 washes for 15 min with 0.2X SSC, 
0.1 % SDS at 47 °C. The membrane was dried and exposed to a Phosphorlmager screen at 
room temperature. The screen was scanned and quanti ta ted using a Phosphorlmager 400A and 
ImageQuant 3.3 software (Molecular Dynamics). 
The "house-keeping" gene glyceraldehyde-3-phosphate dehydrogenase (gpdh) was 
used to normalize RNA loading. Before reprobing, the 32P-24p3/uterocalin probe was 
removed from the membrane by boiling the membrane twice for 3 min in 0.1 X SSC, 0.1 % 
SDS. The striped membrane was pre-hybridized, hybridized with 32P-labeled gpdh probe, 
washed and exposed to a Phosphorlmager screen as described above. 
RT-PCR using the SuperScript™ One-Step RT-PCR kit from Invitrogen Life 
Technologies was performed on 1 |lg of total RNA. Uterocalin cDNAs were amplified using 
0.2 JAM of the primers QL921 (5' GGGGGCTCGAGAGACCTAGTAGCTGTGGAAA 3 ) 
and QL920 ( 5' GGGGGAAGCTTGGGGGCATGTATTTATTCAG 3 ). Gpdh cDNA was 
amplified using 0.2 flM of the primers GPDH5 (5' TGT GGATGGCCCCTCTGGAAA 3') 
and GPDH3 (5' GTTTCTTACTCCTTGGAGGC 3 ). The cDNA synthesis was done at 50 °C 
for 30 min followed by a pre-denaturation step at 94 °C for 2 min. The PCR amplification 
consisted of 40 cycles (94 °C for 15 s, 60 °C for 30 s, 72 °C for 50 s) and a final extension 
step at 72 °C for 10 min using the DNA engine Opticon (MJ Research). The RT-PCR 
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products were resolved on a 1.5 % agarose gel, containing 0.5 lig/ml ethidium bromide using 
TAE buffer (40 mM Tris, 40 mM acetic acid, 1 mM EDTA pH 8.5) at 80 V for 1 h. 
Immunohistochemistry 
Embryos at different days of gestation were dissected and rinsed in PBS (140 mM 
NaCl, 2.7 mM KC1,10 mM NagHPO,, 1.8 mM KH2P04, pH 7.4). The embryos were then 
fixed in 2 % paraformaldehyde in 140 mM NaCl, 20 mM sodium phosphate pH 7.0 for a 
minimum of 12 h. The embryos were then processed for paraffin embedding and 5 p,m 
sections were prepared by the Histopathology Laboratory at the Department of Veterinary 
Pathology (Iowa State University). 
The slides were warmed at 60 °C for 30 min using a slide warmer (Chicago Surgical 
and Electric Co.). All subsequent steps were performed at room temperature using Vectastain 
Elite® ABC (Vector). The melted paraffin was removed by incubating twice in xylene for 
3 min each followed by 3 min in 100 % ethanol. The tissue were rehydrated by incubation for 
3 min in 95 % ethanol followed by 3 min in 70% ethanol and finally 3 min in glass distilled 
water. The sections were incubated in 3 % hydrogen peroxide, 10 % methanol in PBS and 
washed twice (5 min each) in PBS twice. The slides were blocked in blocking solution 
(1:70 normal goat, 0.2% bovine serum albumin (immunohistochemical grade, Vector), in 
PBS) for 30 min. The blocking solution was removed and replaced with fresh blocking 
solution containing rabbit antiserum 87Rb07e against 24p3/uterocalin or the pre-immune 
rabbit serum at a final dilution of 1:500 or 1:700. After incubation for 1 h, the slides were 
washed. The sections were then incubated with biotinylated anti-rabbit IgG in blocking 
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solution (1:100) for 30 min. After washing the sections twice (5 min each) in PBS, the ABC 
reagent (pre-incubated 30 min) was added for 30 min. The sections were washed twice (5 min 
each) in PBS, and DAB substrate, prepared according to manufacturer's instructions (Vector), 
was added for 7 min. After washing twice (5 min each) in glass distilled water, the sections 
were counterstained for 10 min using Weigert's iron hematoxylin stain (19). The slides were 
rinsed with glass distilled water, differentiated in acid alcohol (1 % v/v HC1 in 70 % ethanol), 
rinsed until bright blue in ammonia water (0.2 % v/v ammonium hydroxide in water) and 
washed under running deionized tap water for 10 min. The tissue were dehydrated by 
incubating for 3 min in the following solutions: 70 %, then 95 %, then 100 % ethanol, and 
twice in xylene. Coverslips were mounted on the tissue sections with Permount (Fisher). 
RESULTS: 
Detection of24p3/uterocalin mRNA in embryonic spine by RT-PCR 
The rat homolog of 24p3/uterocalin is expressed during endochondral bone formation 
in gestational day 17 tibia (16). The spine also undergoes endochondral ossification (20) 
during the formation of the vertebrate bone in the mouse embryo. In order to determine 
whether the spine could express 24p3/uterocalin, the mRNA presence in embryonic spine was 
examined by RT-PCR. 24p3/uterocalin mRNA was detected in spine isolated from embryos 
from days 13 to 19 of gestation (Figure 1). 
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Figure 1: 24p3/uterocalin detection by RT-PCR on embryonic spine. 
RT-PCR was performed on 1 |ig of total RNA isolated from spines of embryos collected at day 13 (el 3), day 15 
(el5), day 17 (el7) and day 19 (el9) of gestation. The positive control for 24p3/uterocalin (24p3 +Cont.) was 
obtained by RT-PCR using 1 p.g of total RNA isolated from a day 1 post partum uterus. For gpdh amplification, 
the primers GPDH5' and GPDH3 were used. For 24p3/uterocalin amplification, the primers QL921 and QL922 
were used. The amplified cDNA were electrophoresed on a 1.5 % agarose gel. 
24p3/uterocalirt mRNA expression in embryo, newborn, juvenile and adult mice 
To compare the levels of 24p3/uterocalin mRNA expressed during the period from 
late-gestation embryo to adult female mouse, data was gathered for the spine, liver, and 
spleen. During development, these tissues are involved in the formation and regulation of 
blood cell lineages. All three tissues investigated expressed 24p3/uterocalin mRNA at one 
point during the life of the mouse. The embryonic liver expressed the highest amounts of 
24p3/uterocalin mRNA when compared to the other two embryonic tissues (Figure 2). The 
highest amount of 24p3/uterocalin in the liver was found during late embryonic development 
and decreased after birth to be undetectable in 3 week old mouse. In the spleen, the juvenile 
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mouse had high levels of 24p3/uterocalin mRNA on days 8 and 21 of age. However, spleenic 
24p3/uterocalin mRNA levels decreased after day 49. In the spine, the levels of 
24p3/uterocalin mRNA increased throughout gestation and then over the life time of the 
mouse (Figure 3). The levels of 24p3/uterocalin mRNA in the 49 day-old mice were probably 
underestimated due to a low quantity of total RNA applied in these lanes (Figure 2A). The 
levels of 24p3/uterocalin mRNA in the tail during gestation and over the life time of the 
mouse were also examined, but no significant levels of expression were detected (Figure 2). 
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Figure 2: Expression of 24p3Aiterocalin in murine spine, liver, spleen and tail during aging. 
Panel A: Total RNA from spine, Panel B: Total RNA from liver, Panel C: Total RNA from spleen. Panel D: 
Total RNA from tail. For each panel, 30 tig of total RNA isolated from each tissues were resolved on an agarose 
gel and stained with ethidium bromide to determine the relative amounts of 28S and 18S rRNA for equal loading 
(first panel). The positive control for 24p3/uterocalin (+ control) was 5 |ig of total RNA from a day 1 post­
partum uterus After transfer, the blots were all treated as one. 24p3/uterocalin was detected by blot exposure and 
detection via a Phosphorlmager screen. After developing the screen, the blot was stripped off the 24p3/uterocalin 
probe and gpdh was detected by blot exposure and detection via a Phosphorlmager screen. The days at which the 
tissues were collected are gestational day 17 (el7), day 18 (el8), day 19 (el9) for embryonic tissues. For juvenile 
and adult female mice the tissues were collected at lday (dl), 8 days (d8), 21 days (d21), 49 days (d49), 116 days 
(dl 16) after birth. 
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Figure 3: mRNA quantitation in murine spine, liver and spleen. 
The intensity of the bands from the Northern blots shown in Figure 2 were quanti tared (ImageQuant software). 
The quantitative data of 3 other blots were added to determine the profile of expression in the embryonic spine. 
Ratio of the counts present in 24p3 band over the counts present in the gpdh band was used to normalized the 
data, and the value of the ratio was arbitrarily assigned to 1 for dl liver and spine and for d8 spleen. The error 
bars represent +/- one standard deviation. The embryonic stage at which the tissues were collected are 
represented as el3, e!5, el7, el8, el9 for embryonic tissues collected at gestational days 13, 15, 17. 18, 19 
respectively. For juvenile and adult female mice, the age at which the tissues were collected is represented as dl, 
d8, d2l, d49, dl 16 for tissues collected at 1 day, 8 days, 21 days, 49 days, 116 days after birth. The absence of 
bar indicates that tissues were not examined on that given day. The solid lines above the graph represent the time 
when hematopoiesis takes place, the dashed line shows the presence of hematopoiesis but the organ is not the 
major location of hematopoiesis at that time. 
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Detection of uterocalin protein by immunohistochemistry 
To determine if the 24p3/uterocalin protein could be detected in the tissues where the 
mRNA was detected, immunohistochemistry was performed on mid-sagittal section of 
embryos from gestational day 11 to day 19. 
No specific protein signal was observed on mid-sagittal sections of any of the embryos 
examined. A cross-section of a day 1 postpartum uterus was used as a positive control and 
showed an expected pattern of staining in the luminal and glandular epithelium (data not 
shown). The antiserum background staining was minimal. The absence of signal 
suggested that the local protein concentration was undetectable by immunohistochemisty, or 
24p3/uterocalin was secreted to another location. 
DISCUSSION: 
The study of 24p3/uterocalin mRNA expression in the liver, spleen and spine provides 
additional insight on the location of 24p3/uterocalin expression during mouse embryogenesis 
as well as during aging. The 24p3/uterocalin mRNA profile in the spleen of female mice was 
similar to the profile previously reported in male mice (9). In addition, detectable levels of 
24p3/uterocalin mRNA were observed as late as 116 day old in female. No major transitions 
in the role or anatomy of the spleen occur between day 21 and 49 when the levels of 
24p3/uterocalin drop dramatically. However, mice are weaned around day 21 and become 
sexually mature around day 35. A more detail analysis of the 24p3/uterocalin mRNA levels 
between day 21 and 45 in male versus female mice could suggest a function of the spleen 
which is related to weaning or sexual maturation. 
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The high levels of 24p3/uterocalin in day 8 female mouse liver rapidly decreased to be 
at their lowest level at day 21. The profile of 24p3/uterocalin mRNA in the liver of 10 day old 
and adult male mice showed high expression. The mRNA plateaued by day 45 and declined to 
undetectable limits by 75 days in the adult mouse (9). This difference in the 24p3/uterocalin 
profile in the young and adult mouse is unclear but could be related to the sex or strain of the 
animals used in each study. The determination of the mRNA profile in the embryonic and the 
newborn mouse liver adds new insight to possible roles of 24p3/uterocalin during gestation. 
The period of expression in the liver corresponds to the period when hematopoiesis actually 
takes place in the liver before its slow and gradual transition to the permanent localization of 
hematopoiesis to the bone marrow at gestational day 15 (21). Before determining a function 
for 24p3/uterocalin in the liver, it will be critical to determine the cell type expressing the 
mRNA. 24p3/uterocalin might be involved in the transition of hematopoiesis from the liver to 
the bone marrow by the removal of specific cells from the liver via apoptosis. This role is 
suggested by the induction of apoptosis in proB-lymphocytes, cells involved in hematopoiesis, 
by 24p3/uterocalin (14). Conversely, the proposed protective role of 24p3/uterocalin during 
the acute phase response and tissue involution could be involved in protecting fetal liver from 
degradation by leukocytes present during hematopoiesis in the fetal liver. 
Most interestingly, 24p3/uterocalin levels in the spine increased as the animal aged. 
The rapid increase between gestational day 19 and day 1 newborn mice correlates with the 
observation that transition of hematopoiesis to the bone marrow intensifies around birth (22). 
The levels of 24p3/uterocalin were the highest in the 116 day old spine. It is not clear why as 
the animal ages, the level of 24p3/uterocalin increases. The continued increase in 
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24p3/uterocalin message as the animal ages, could also be linked to the way total RNA was 
collected. Whole spines were used to isolate RNA until the animals were 8 days old. After 21 
days of age, only the thoracic region was used to isolate RNA. The undetectable levels of 
mRNA in the tail suggests that the thoracic portion of the spine contains most of the 
24p3/uterocalin mRNA. Thus, it is possible that the total RNA population was enriched with 
24p3/uterocalin mRNA in the older mice compared to the embryonic and younger mice. 
Interestingly, the bone marrow in the spine of the thoracic region is where most of 
hematopoiesis takes place (23). 
The data described here, along with the correlation of 24p3/uterocalin expression 
under conditions associated with apoptosis and tissue remodeling allows for the formation of a 
hypothesis that would implicate a role for 24p3/uterocalin in hematopoiesis, particularly 
during embryogenesis. 
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CHAPTER 5. 
GENERAL CONCLUSIONS 
MRP/PLFs are members of the prolactin-growth hormone family. They are 
glycoproteins secreted by the placenta during mid-gestation and are thought to play a role in 
both angiogenesis during neovascularization of the uterus and in stimulation of uterine cell 
proliferation. To gain insight into the role of MRP/PLFs in the uterus during mid-gestation, I 
became interested in studying the interactions between MRP/PLFs and its uterine receptors) 
as well as the role played by the carbohydrate moieties of MRP/PLFs in mediating the ability 
of MRP/PLFs to bind to the uterine receptor. I also was interested in studying the transduction 
pathway(s) of MRP/PLFs after activation of the uterine receptor. 
To begin studying the roles of MRP/PLFs during mid-gestation, some of the 
physiological changes occurring in the utero placental compartment were characterized 
throughout gestation. Examination of the uterus during the course of gestation demonstrated a 
parallel increase in wet weight and in DNA content. This increase is correlated with the peak 
of secretion of MRP/PLFs by the placenta from gestation days 11 to 14 and supports the 
hypothesis that MRP/PLFs are involved in uterine maintenance and development. 
To understand the glycoprotein-ligand interaction with the uterine receptor, cDNA 
expression vectors were created for the different MRP/PLF family members. All four known 
mrp/plfs cDNAs were modified to include a removable N-terminal histidine tag. Recombinant 
proteins were successfully expressed and purified from the conditioned medium of stably 
transfected human 293 cells. Experiments were designed to examine the ability of the 
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recombinant MRP/PLF family members to bind uterine membranes and stimulate DNA 
synthesis in uterine cells. The results obtained and summarized in Chapter 3 were significanUy 
different to those previously described (1), (Rosenzweig, unpublished data). 
The absence of 3H-thymidine incorporation in minced uterine organ and primary 
uterine cell cultures upon addition of recombinant MRP3 (with or without the histidine tag) 
suggested that recombinant MRP/PLF secreted by 293 cells was non-active (Chapter 2). 
However, several difficulties were encountered with both minced uterine organ and primary 
uterine cell cultures. In the uterine organ cultures, Rosenzweig observed a 2 to 3 fold increase 
in thymidine incorporation upon the addition of MRP/PLF purified from BN/L cells. In 
general, previous reports (Rosenzweig, unpublished data) and my observations showed that 
uterine organ culture incorporated low numbers of TCA precipitable counts with high 
variability which is incompatible with the small increases in 3H-thymidine incorporation. 
The increase in 3H-thymidine incorporation by quiescent Swiss 3T3 cells stimulated by 
untreated serum (data not shown) or primary keratinocytes stimulated with KGF (Data not 
shown) showed that 3H-thymidine incorporation can be detected in different cell types 
attached to coverslips. Data from Rosenzweig, showed that MRP/PLF isolated from BN/L 
cells gave a 4 to 5 fold increase in 3H-thymidine incorporation in primary uterine cell culture 
isolated by the method described in Nelson et al. (1). The optimum conditions for 3H-
thymidine incorporation were observed when day 11 uterine primary cell cultures were treated 
with 5 ng/ml MRP/PLF for 30 hours followed by a 4 hour pulse with 8 |lCi/ml 3H-thymidine 
(Nilsen-Hamilton lab, unpublished data). 
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However, when primary uterine cell cultures were isolated for an independent repeat of 
the 3H-thymidine incorporation assay, these cells did not have the growth characteristics 
observed when previously prepared by Rosenzweig. Different batches of fetal calf serum were 
tested to regain the original cell growth characteristics. In addition, techniques for cell 
isolation and cell attachment were modified to reestablish the cell growth characteristics 
observed by Rosenzweig. McCormack et al. described a method to isolate different rat uterine 
cell types. This method was used to isolate day 11 mouse uterine stromal and epithelial cells. 
The mouse uterine cells isolated by this method had similar growth and morphological 
characteristics to the one reported by McCormack et al. (2). After re-establishing the day 11 
uterine cell cultures, several MRP/PLF preparations purified from Swiss 3T3 cells (3), BN/L 
cells (1), baculovirus (Nilsen-Hamilton lab, unpublished results) and more recently 
recombinant His-PLFl, His-MRP3 and MRP3 without the histidine tag (Chapter 2) were 
tested for their ability to stimulate 3H-thymidine incorporation. However, no significant 
incorporation was observed when the different uterine cells types were treated with the various 
MRP/PLF batches as mentioned above. 
Interestingly, after examination of the cell morphology, the cells incorporating high 
tritium counts had a different morphology as compared to the cells associated with low tritium 
counts. A time course of basal 3H-thymidine incorporation compared with the associated 
morphology of non-stimulated day 11 uterine cells showed that a switch in morphology is 
associated with a rapid drop in 3H-thymidine incorporation (data not shown). This suggests 
that without the addition of any growth factors, the uterine cells in culture underwent 
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differentiation and decreased their DNA synthesis. If one of the two cell types is unresponsive 
to MRP/PLFs this could account for the high variation in counts observed in the assay. 
In conclusion, the lack of 3H-thymidine incorporation in the minced uterine organ and 
primary uterine cell cultures upon stimulation with MRP/PLF, isolated from several cell types, 
suggests the presence of contaminant(s) in the protein preparations. The contaminant(s) 
present in the MRP/PLFs isolated from Swiss 3T3 cells, BN/L cells, baculovirus, or 293 cells 
inhibited the 3H-thymidine incorporation of the uterine cells. Conversely, contaminant(s) 
present in the original BN/L preparation used in Nelson et al. (1) increased the 3H-thymidine 
incorporation of the uterine cells. 
The receptor binding activity of His-MRP3 was tested on isolated membrane 
preparations. This method decreases the number of parameters associated with tissue culture, 
like cell type and serum lot, for example. MRP3 with or without its histidine tag did not bind 
specifically to day 16 maternal liver (4) or day 11 uterine (1) membrane preparations. The 
absence of binding to these liver membranes suggested that His-MRP3 or MRP3 isolated from 
293 cells was unable to bind to the IGF H/mannose-6-phosphate (IGFD/M6P) receptor. The 
presence of the IGFH/M6P receptor on day 16 liver membrane preparations was confirmed 
with the successful binding of IGF-II. Furthermore, presence of mannose 6-phosphate on the 
His-MRP3 was demonstrated in an overlay assay using the bovine IGF-D/M6P receptor. 
Interestingly, in the overlay assay only 50 % of the His-MRP3 could be bound by the bovine 
IGF-0/M6P receptor, indicating either that 293 cells do not add mannose 6-phosphate 
efficiently or the glycosidic residues were dephosphorylated subsequent to secretion. High 
affinity binding of glycoproteins to the IGF-D/M6P receptor requires the presence of several 
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mannose 6-phosphates on the same glycoprotein to allow efficient dimerization of the 
receptor (5). It is possible that in the overlay assay the highly localized concentration of His-
MRP3 on the nitrocellulose membrane, allowed for an artificial concentration of mannose 6-
phosphate residues enabling high affinity binding of the IGF-D/M6P receptor. In solution, this 
localized concentration of mannose 6-phosphate would not occur and the low affinity of the 
IGFD/M6P receptor for His-MRP3 resulted in no detectable binding activity in the day 16 
liver membrane binding assay. 
The source of the protein utilized in the day 16 liver membrane assay by Lee and 
Nathans was recombinant PLF1 from CHO cells, whereas the protein used in Chapter 3 was 
recombinant MRP3 (different from PLF1 by 2 amino acids) purified from 293 cells. PLF1 and 
MRP3 have the same number of putative N-glycosylation recognition sequences indicating 
that they can potentially be glycosylated identically. Therefore if glycosylated properly, PLF1 
and MRP3 should both bind to the IGFD/M6P receptor which is mainly mediated by the 
carbohydrate moiety rather than the protein moiety of glycoproteins (6-10). However, reports 
are suggesting that CHO cells and 293 cells generate different glycosylation patterns (11, 12). 
It is then possible that the 293 cell glycosylated-MRP3 has a glycosylation pattern such that it 
has low binding affinity for the IGFII/M6P receptor. This could be tested by comparing PLF1 
or MRP3 isolated from CHO cells with PLF1 or MRP3 isolated from 293 cells using the 
method described by Lee and Nathans on day 16 liver membrane preparations using the filters 
described in their procedure (4). 
If the glycosylation pattern of PLF1 and MRP3 isolated from 293 cells leads to the 
absence of binding to the M6P receptor, it could also be responsible for the absence of binding 
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to the uterine membranes. This would suggest that the uterine receptor is sensitive to the state 
of glycosylation of the MRP/PLFs. Also, it is possible that a contaminant present in the 
conditioned medium of 293 cells co-purified with MRP3 and inhibited binding to the uterine 
and IGFD/M6P receptors. 
Finally, the Appendix section has described the optimization of the rat lymphoma Nb2 
cell prolactin receptor assay. This binding assay was designed to test if the removal of the 
carbohydrates from MRP/PLFs would stimulate the prolactin receptor in the NB2 cells to 
determine if the carbohydrates on MRP/PLFs are preventing the recognition of this prolactin-
growth hormone family member to the receptor. This assay was to be used in parallel with the 
uterine membrane receptor assay to see if glycosylation could also regulate the activity of the 
MRP/PLF receptor, this would further identify and characterized the protein-receptor 
interactions with the uterine receptor. 
The lipocalin 24p3/uterocalin was discovered similarly to MRP/PLF by adding growth 
factors to quiescent mouse fibroblasts 3T3 cells. However, unlike MRP/PLF, 24p3/uterocalin 
secretion is superinduced by the addition of the protein synthesis inhibitor cycloheximide. 
Like MRP/PLF, 24p3/uterocalin is expressed during gestation although MRP/PLF secretion is 
limited to the trophoblastic giant cells while 24p3/uterocalin is expressed in several tissues, 
both maternal and fetal. 
Discovering the cell type(s) expressing 24p3/uterocalin in the liver, spleen and spine 
should help determine whether 24p3/uterocalin is expressed by the hematopoietic cells, like 
B-lymphocytes (13), neutrophils as shown in the human equivalent NGAL (14), other 
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hematopoietic cell types or possibly other cell types presently not known to express 
24p3/uterocalin. 24p3/uterocalin could also be expressed in chondrocytes of the spine as 
demonstrated in the rat and chicken homologues (15). The cell type(s) expressing the 
24p3/uterocalin mRNA could be determined by in situ hybridization as preliminary 
experiments suggest that the protein is not accumulating locally at levels detectable by 
immunohistochemistry (Chapter 4) Also, because 24p3/uterocalin is a secreted protein, in situ 
hybridization will be necessary to really establish the cell type(s) expressing it. 
The results reported in Chapter 4 for the expression in the liver and spleen of juvenile 
and adult mice were similar to the one obtained by Garay-Rojas et al. (16) with discrepancies 
in the endpoint of the time course of expression. The different sex of the mice used in both 
studies may have caused the observed differences in 24p3/uterocalin mRNA down-regulation 
in the adults. Several proteins (17-20) are known to be differently regulated in the liver of 
male and female. It is possible that 24p3/uterocalin is also differently regulated according to 
the sex of the animal in the liver, spleen and spine. For both the liver and spleen, the 
completion of expression profile during gestation and in the young mouse might also shed 
light on the possible roles played by 24p3/utèrocalin in these organs. 
During late embryogenesis, the fetal liver is the site of hematopoiesis and at birth the 
hematopoiesis is mainly relocated to the bone marrow of several bones. To further study a 
possible role of 24p3/uterocalin for hematopoiesis in the liver, the co-culture of fetal liver 
cells and pre-hepatic hematopoietic stem cells could be used to examine the effects of 
24p3/uterocalin in these cell types. Takeuchi et al., using an immature hepatocyte and 
hematopoietic stem cell co-culture, showed that the immature hepatocytes could support the 
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proliferation and maturation of hematopoietic stem cells in rhe liver. However, hepatocytes, as 
they mature in culture, can no longer support hematopoiesis. Thus the hematopoietic stem cell 
population will migrate to the bone marrow (21). The role of 24p3/uterocalin in the liver 
during hematopoiesis may be examined in this cell culture system by looking at expression 
levels of 24p3/uterocalin in the different cell types and observing whether the addition of 
purified 24p3/uterocalin to the liver and hematopoietic cells perturbs the ability of fetal 
hepatocytes to support hematopoiesis in vitro. 
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APPENDIX. 
DEVELOPMENT OF A LACTOGENIC RECEPTOR BINDING ASSAY 
TO TEST DIFFERENT PROLACTIN GROWTH HORMONE FAMILY 
MEMBERS 
ABSTRACT: 
MRP/PLFs are secreted glycoproteins of 34 kDa belonging to the prolactin-growth 
hormone family. MRP/PLFs are synthesized by the placenta, more precisely by the 
trophoblastic giant cells, during a short period of time ranging from day 10 to day 13 of 
gestation. A receptor for MRP/PLFs was found in vitro and maximum binding activity was 
observed on day 11 uterine membrane preparations. Maternal-fetal communications can be 
achieved, through the receptor for MRP/PLFs when the placenta (fetus) sends a signal 
(MRP/PLFs) to the uterus (mother). The nature of the signal appears to be stimulation of 
uterine cell proliferation as demonstrated by the increase in 3H-thymidine incorporation by day 
11 uterine primary cell cultures. Reported here are data showing the modification of the Nb2 
cell prolactin binding assay. The assay time was decreased from 72 h to 15 h using 3H-
thymidine incorporation instead of cell counting to determine cell proliferation after 
stimulation by a lactogenic hormone. The Nb2 cell prolactin binding assay was used to show 
that MRP/PLFs did not act through the prolactin receptor. The data also showed that prolactin 
did not act through the MRP/PLF receptor, but prolactin inhibited the effect of MRP/PLF on a 
uterine primary cell system. 
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INTRODUCTION: 
This appendix summarizes the research I did during May-July, 1994 in the Nilsen-
Hamilton laboratory. This research provided the data which was used as the supporting thesis 
for the Master's of Science and Technology in "Biochemical and Biological Engineering" 
degree obtained in September 1994 from the Université Paris XII Val de Marne. For this 
appendix, I wrote an Introduction section different from the original thesis, revised the text for 
the Materials and Methods, and Results sections and rewrote the Discussion section with 
updated references. 
Rat lymphoma Nb2 cells were derived from malignant lymphomas that arose in the 
lymph node of a Noble (Nb) male rat which had been treated with estrogen. Gout et al. 
established a suspension cell culture from a singular node, Nb2 (1). It was found that the Nb2 
cells doubled every 15 hours in medium containing fetal calf serum, but when the media was 
switched to horse serum (HS) the cells stopped replicating. These stationary cells could 
resume growth in HS upon the addition of prolactin (PRL) (1, 2). Tanaka et al. used this 
property to develop a specific bioassay for binding ligands to the prolactin receptor based on 
the resumption of growth of the stationary cells by the addition of lactogenic hormones (2). 
The previous bioassays for the detection of prolactin receptor binding involved the pigeon 
crop sac stimulation assay (3), in vitro mammary gland cell cultures (4), or radioreceptor 
binding assay with l25I-labeled PRL on mammary gland membrane extracts (5). These assays 
were not very sensitive, technically difficult and had tedious methodology. 
The Nb2 cell bioassay was used to test the role played by the glycosylation of MRP/PLFs 
in receptor recognition. Prolactin, placental lactogen and growth hormone do not bind to the 
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uterine receptor for MRP/PLFs (6). Conversely, MRP/PLFs do not have lactogenic activity, 
i.e. do not activate the prolactin receptor as demonstrated by the pigeon crop assay and the 
Nb2 cell bioassay (7). The high amino acid homology between all the prolactin-growth 
hormone family members suggests a similar three-dimensional protein structure. Prolactin, 
placental lactogen and growth hormone can all bind to the prolactin receptor (2). MRP/PLFs 
are heavily ^-glycosylated compared to the hormones that can bind to the prolactin receptor. 
To investigate the role of glycosylation in receptor binding and activation, a chemical 
deglycosylation method was used to deglycosylate MRP/PLFs (7). This deglycosylated 
MRP/PLF was tested in both the uterine primary cell culture assay (MRP/PLF receptor 
binding), and the Nb2 cell bioassay (prolactin receptor binding). 
In this appendix, the successful modification of the Nb2 cell bioassay provided a faster 
Nb2 cell bioassay decreasing the assay time from 72 hours to 15 hours by the use of 3H-
thymidine incorporation by the cells resuming growth rather than single cell counting. The 
absence of MRP/PLF binding to the prolactin receptor was verified. Also shown is the 
preliminary data on the possible effect of prolactin on the uterine primary cell culture response 
to MRP/PLFs. The chemical deglycosylation method showed that it would require milligram 
amounts of MRP/PLF to yield sufficient deglycosylated protein for further testing. 
MATERIALS AND METHODS: 
Animals and reagents 
The mice used for the uterine primary cell cultures were from the CF-1 strain. The 
animals were cared according to the "N1H guidelines for the care of laboratory animals" with 
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free access to food and water. The experimental protocols were approved by the Committee on 
Animal Care and Use of Iowa State University. 
Nb2 cells were a gift from D. Prentice (Indiana State University, Terre Haute, IN). 
MRP/PLFs were purified in the laboratory from conditioned medium of a BN/L cell line or a 
transacted (by bacculovirus) insect cell line. Mouse prolactin was a gift from A.F. Parlow 
(Harbor-UCLA Medical Center, Torranco, CA). Mouse placental lactogen I (PL-I) was a gift 
from F. Talamentes (University of California, Santa Barbara, CA). Ovine prolactin o-PRL 
from pituitary gland and porcine growth hormone (pGH) were purchased from Sigma. Rabbit 
anti-MRP/PLF antiserum was prepared in the laboratory using purified MRP/PLFs from 
conditioned medium of Swiss 3T3 cells. All the sera were purchased from Hy-Clone, except 
for the horse serum used for the stationary medium of Nb2 cells which was purchased from 
Gibco Invitrogen Corporation. Gibco was also the source of tissue culture supplies unless 
specified otherwise. The different HS tested for the stationary medium were from Hyclone (1 
lot), Gibco Invitrogen Corporation (1 lot), Sigma (2 lots). Cells were counted using a 
hemocytometer or a Coulter counter®. Radioactivity uptake in tissue culture samples was 
determined using 5 ml of Scintiverse BD cocktail (Fisher) and counted in a Liquid 
Scintillation Analyzer (Packard 1900TR). 
Coverslips used for cell growth were boiled in 1 % Calgon-metasilicate (8.8 g/1 Calgon, 
79 g/1 sodium metasilicate), rinsed, boiled 10 min and rinsed in distilled water, then absolute 
alcohol. After drying, the coverslips were sterilized 4 h at 350 °C. 
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Nb2 cell bioassay 
The cells were grown and prepared as previously described by Tanaka et al. (2). The Nb2 
cells were grown as suspension cultures in 25cm2 flasks (Costar) in growth medium (Fischer's 
medium supplemented with 10 % horse serum, 10 % calf serum, 10"4 M 2-mercaptoethanol, 
20 units/ml penicillin/streptomycin). All incubations were done at 37 °C in 5 % C02. 
Nb2 cells were induced in the stationary phase by transferring them to a "stationary" medium 
(growth medium without calf serum) for 24 h to slow down their rate of replication. The cells 
were collected by centrifugation (10 min at 1000 x g), and resuspended in "stationary" medium 
at a concentration of 5 xlO5 cells/ml, and 1 ml was aliquoted in each well of a 24 well tissue 
culture plates (Costar). 
Samples to be assayed for prolactin binding activity were incubated with the stationary 
cells for 9 hours followed by an additional 4 hours with 4 |lCi/ml of methyl-3H-Thymidine 
(Amersham). Thymidine incorporation was stopped by centrifuging the cells for 10 min at 
10,000 x g and the cell pellet was incubated at 0 °C with 10 % triChloro-acetic acid (TCA) for 
2 min. The mixture was vortexed and filtered on borosilicate microfiber filters (MPS). The 
filters were washed with 5 ml of 10 % TCA followed by a wash with 95% ethanol, air dried, 
and the TCA precipitable counts were determined by scintillation counting. 
Primary uterine cell culture 
The method used in the laboratory was adapted by Nitza Rosenzweig from the method 
described by Ghosh et al. (8). Uteri from CF-1 mice at day 11 of gestation were collected 
aseptically in Ca2>, Mg2* free Hank's balanced salt solution (HBSS). The uterine horns were 
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slit open to remove the embryos and placentae, cut into small pieces, and placed in a sterile 
trypsin solution (0.1 % type IE bovine trypsin (Sigma), 0.03 M EDTA in HBSS) for 20 to 24 h 
at 4 °C. The trypsin solution was removed, and the uteri were incubated at 37 °C for 1 h. 
Warm HBSS plus Ca2\ Mg2* was added and the tissue was vortexed for 5 min at high speed. 
The dissociated tissue was allowed to settle at 1 x g for 5 minutes in the bottom of a 50 ml 
centrifuge tube and the cell suspension was collected and centrifuged (10 min at 1000 x g). 
The cell pellet was «suspended in 5 ml of HBSS plus Ca2\ Mg2* containing 0.3% BSA. 
Clumps and sheets of epithelial cells were allowed to settle to the bottom of a 5 ml centrifuge 
tube, at 37 °C, for 5 min. The supernatant containing the fibroblasts, endothelial, muscle and 
stromal cells was carefully transferred and centrifuged 10 min at 1000 x g to collect the cells. 
Freshly isolated cells were resuspended in growth medium, DMEM high glucose with 
10 % heat inactivated fetal calf serum, 10 ng/ml porcine insulin (Sigma), and 20 units/ml 
penicillin/streptomycin. The cells were plated at a density of 1.25 xlO5 cells/well on coverslips 
(1% Calgon-metasilicate treated) in 24 well plates and incubated at 37 °C in 10 % CO,. After 
24h, an equal volume of fresh medium was added and then half of the medium was changed 
every two days. Typically, the cells were confluent after two weeks. 
Half the medium was removed from confluent cell cultures and replaced with medium 
containing the various reagents to be assayed. The cells were incubated for 30 h followed by 
additional 4 hours with 8 pCi/ml of methyl-3H-thymidine. The cells were washed in TBS 
(140 mM NaCl, 8 mM Na^HPO,, 2.7 mM KC1,1.5 mM KH2P04,0.68 mM CaCl,, 0.5 mM 
MgClj pH 7.5) and fixed in 3.7 % formaldehyde, 0.11 M I^SO,, 0.09 M NaCl overnight at 
RT. The fixed cells on coverslips were incubated in ice cold 10 % TCA for 30 min, followed 
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by two washes with 95 % ethanol and air dried. The amount of methyl-3H-thymidine 
incorporated by the cells was then determined by scintillation counting 
Chemical deglycosylation with TFMS 
MRP/PLF (approximately 20 |ig) plus other glycoproteins (to have a total of 40 |lg of 
protein) were dried under vacuum at room temperature. The dried proteins were treated with 3 
Hi of anhydrous Trifluoro methane sulfonic acid (TFMS) (Sigma) (9). The reaction mixture 
was incubated with occasional shaking at 0 °C for 1 h under nitrogen in a 1.5 ml tube. 
Subsequently, the reaction mixture was cooled at -20 °C (in a dry ice-ethanol bath) and 
neutralized by gradually adding 60 % pyridine (cooled at -20 °C) to prevent overheating as the 
neutralization is exothermic. 
SDS polyacrylamide gel electrophoresis 
Samples to be separated by SDS PAGE were loaded on a 12 % acrylamide gel and 
electrophoresis was completed at 12.5 mA for 6 h in 0.4 M Glycine, 50 mM Trizma, 1 % SDS 
pH 8.35. The molecular weight markers were bovine serum albumin (66 kDa), ovalbumin 
(45 kDa), carbonic anhydrase (33 kDa), Myoglobin (18 kDa), Cytochrome c (12.5 kDa). 
Proteins bands were detected by Coomassie blue followed by silver staining (10). 
Western Blot Analysis 
Samples containing MRP/PLFs were first resolved by SDS-PAGE. The proteins were 
transferred onto nitrocellulose membranes (Nitrobind 0.45 |lm, Osmonics) in 25 mM Trizma, 
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190 mM Glycine and 20% Methanol pH 8.3, using a Hoefer TE50 apparatus at 360 V for 1 h 
at 4 °C. The membrane was stained with 0.2 % Ponceau S in 3 % trichloroacetic acid to 
ascertain uniform protein transfer to the membrane. After destaining with water, the 
membrane was incubated overnight at 4°C in blocking solution (5 % wt/vol nonfat milk in 
0.14 M NaCl, 5 mM KC1,0.7 mM NagHPO,, 25 mM Tris, pH 7.5,0.02 % wt/vol Na azide). 
The blocking solution was removed and replaced with fresh blocking solution containing a 
rabbit anti-MRP antiserum (recognizing PLF1, PLF2, MRP3, MRP4) at a final dilution of 
1/200. After incubation at room temperature for 90 min, the membrane was washed three 
times (10 min each) in wash buffer (140 mM NaCl, 2.7 mM KC1, 1.5 mM KH2P04, 8 mM 
NagHPO*, pH 7.5). The first wash contained 0.1 % Tween 20. The membrane was then 
incubated for 30 min at room temperature with goat anti-rabbit IgG conjugated to peroxidase 
(Pierce) diluted 1:5000 in wash buffer. The membrane was washed three times (10 min each) 
in wash buffer, with the first wash containing 0.1% Tween 20. The presence of peroxidase 
activity was detected by electro-chemiluminescence using ECL™, (Amersham Pharmacia) and 
exposing to x-ray film (Kodak). 
RESULTS: 
Characterization of the Nb2 cell culture 
The initial growth curve of Nb2 cells obtained in the laboratory provided the growth 
characteristics of the particular clone obtained. The cell counts over the span of the growth 
curve were determined with a hemocytometer or a Coulter counter™. Figure 1 represents a 
typical growth curve for Nb2 cells. 
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Figure l:Growth curve of Nb2 cells. 
The cells grown, in the growth medium (see Materials and Methods), were counted with an hemocytometer. Each 
point is the average of four independent counts (the percentage of error on each point was always 10%). 
The doubling time in this particular experiment is 15.4 hours. 
The results from three different experiments gave an average cell doubling time of 15 ± 
1.5 hours. It was noted that the cells stopped growing and began dying at a concentration of 
2 xlO6 cells/ml. However, when the cells were transferred to fresh medium close to the time 
they reached this critical cell number, the growth resumed. 
The fetal calf serum dependency of Nb2 cells was tested by growing them in medium 
supplemented with different percentages of fetal calf serum and calf serum (Figure 2). There 
were no major differences in the doubling times of the cells grown on media containing 
different percentages of fetal calf serum and calf serum, as was reported previously by Gout 
et al. (1). It was established that Nb2 cells can be grown equally well in a medium 
supplemented with calf serum instead of fetal calf serum. In addition, the doubling times for 
this experiment were higher than the one previously determined, but this difference might be 
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explained by the fact that during this experiment the cells were incubated in an CO, 
atmosphere greater than 5 %. 
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Figure 2: Determination ol the need for FCS by Nb2 cells. 
The doubling times of Nb2 cells grown on medium containing different percentage of calf serum (CS) and fetal 
calf serum (FCS), were determined in duplicate. 1:10% FCS, 0 % CS, 2:8 % FCS, 2 % CS, 3: 6 % FCS. 
4 % CS, 4: 4 % FCS, 6 % CS, 5: 2 % FCS, 8 % CS, 6: 0 % FCS, 10 % CS. The cells were counted with a Coulter 
Electronic Cell Counter™ ( threshold 8|im to IS^lm). 
Optimization of the modified Nb2 cell bioassay 
The first parameter optimized was the volume of 10 % TCA needed to wash the filters 
and remove unspecific radioactivity. Four |lCi/ml of 3H-Thymidine were added to growing 
Nb2 cells for 4 hours and the incorporation was determined using the protocol described in 
Materials and Methods with different repeals of 5 ml washes. Figure 3 shows that one wash 
with 5 ml of 10% TCA was enough to diminish the non-specific radioactivity bound to filters 
and have a percentage of error less than 20 %.. It was also determined that the centrifugation 
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step was necessary to remove the serum before doing the TCA precipitation as there were too 
many serum proteins present leading to the clogging of the filters. 
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Figure 3: Determination ol the volume of 10% TCA. 
Growing Nb2 cells were incubated with Thymidine for 4 hours. After centrifugation. they were incubated at 0°C 
with 10 % TCA for 2 min, the radioactivity incorporated was measured by filtering the precipitate. The counts 
obtained on the filters after washing with the indicated volume of 10% TCA were the average of duplicates and the 
error bars represent the standard deviation. 
The optimal concentration of the positive control ovine prolactin (oPRL)was 
determined. The cells were treated as described in the bioassay protocol with various 
concentrations of oPRL (Figure 4.) The saturation curve indicated that the 1 U/ml 
concentration was the minimal concentration of oPRL that gave the highest thymidine 
incorporation by Nb2 cells. 
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Figure 4: Determination of the optimal prolactin concentration. 
Nb2 cells were treated with 0.01,0.1,1 and 6 U/ml of oPRL as described in Materials and Methods. Each point 
represents the mean of duplicate samples. The error bars represent the standard deviation. The background counts 
incorporated by non treated cells were 514 +/- 80.6 
The previous experiments were done with medium supplemented with HS that was 
known to make the cells stationary. Different lots of horse sera (see list of companies in 
Materials and Methods) were tested to identify a new lot of horse serum as efficient as the 
previous one. Figure 5 shows the disparity between different lots of horse serum tested. The 
best horse serum was determined as the one giving the lowest incorporation of 3H-Thymidine 
by the stationary cells and the highest response when treated with oPRL. The cell viability and 
ability to respond to prolactin showed that horse serum (HS2 from Gibco Invitrogen 
Corporation) was the best. 
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Figure 5: Screening of horse sera for the stationary medium. 
The Nb2 cells were «suspended in different stationary medium supplement with the different horse serum. 
Buffer (white) or 1 U/ml ovine prolactin (grey) was added to the cells which were incubated 20 hours followed 
by 4 |ici/ml of 3H-Thymidine addition for 4 hours. The incorporated radioactivity was then measured by TCA 
precipitation and filtration. The values expressed are means of duplicates. 
All the previous prolactin experiments were done with an incubation time of twenty 
hours. Twenty hours was chosen considering the 15 hour doubling time of the cells and that 
cell division would resume with a slight delay. Determination of the optimal incubation time 
for 3H-thymidine incorporation by the Nb2 cells was the final experiment done to optimize the 
modified prolactin receptor Nb2 cell assay (Figure 6). 
Maximal thymidine incorporation was clearly seen after nine hours of incubation with 
prolactin followed by a 4 hour pulse with 4 plCi/ml of 3H-thymidine. 
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Figure 6: Determination of the incubation time with prolactin for the highest thymidine incorporation. 
Stationary Nb2 cells were treated with or without 1 U/ml of o-PRL. At each time point the cells were treated 
according to materials and methods. DNA synthesis is represented as fold-over control (cpm stimulated / cpm 
non-stimulated). 
Effect of MRP/PLF and Prolactin on the uterine primary cell culture 
From previous experiments, an increase in DNA synthesis was seen in cultures of uterine 
cells from day 11 of gestation uteri which were treated with MRP/PLFs (6). Figure 7 shows 
the effect of MRP/PLFs and mouse prolactin (mPRL) on uterine primary cell cultures. 
Mouse prolactin added at two different concentrations (5 ng/ml and 1 |ig/ml) did not 
affect the DNA synthesis of the primary uterine cells, whereas MRP/PLFs increased DNA 
synthesis at a concentration of 5 ng/ml. However, when 5 ng/ml or 1 |lg/ml of mPRL are 
added at the same time as 5 ng/ml of MRP/PLF, DNA synthesis in the primary uterine cells is 
decreased in a concentration dependent manner. 
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Figure 7:Effect of MRP/PLF and prolactin on uterine primary cell cultures. 
Uterine cells plated at 1.25x10s cells per well were grown for 2 weeks to confluency in 14 days and were 
incubated for 30 hours with 1: buffer, 2: MRP/PLF 5ng/ml, 3: mPRL Sng/ml, 4: mPRL 1 ng/ml, 5: MRP/PLF 
5ng/ml + mPRL 5ng/ml, 6: MRP/PLF 5ng/ml + mPRL 1 |ig/ml. The results are expressed as fold-over control 
(cpm incorporated by the cells incubated with a molecule over cpm incorporated by the cells incubated with the 
buffer), the error bars indicates the standard deviations from duplicates. 
Interaction of different molecules with the prolactin receptor 
To verify whether MRP/PLF could act through the prolactin receptor to stimulate DNA 
synthesis, MRP/PLFs and the other members of the prolactin/growth hormone family were 
tested in the Nb2 bioassay (Figure 8). 
This experiment showed that mouse prolactin, mouse placental lactogen I and porcine 
growth hormone, stimulated growth of the Nb2 cells, whereas MRP/PLFs did not. Also, 
MRP/PLFs (5 ng/ml and 0.1 Jlg/ml) were added with mPRL (5 ng/ml) to see if 
MRP/PLFscould modulate binding of mPRL to the prolactin receptor. Figure 8 shows that 
MRP/PLF does not affect the effect of prolactin on the growth of Nb2. 
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Figure 8: Effect of various members of the PRL-GH family on the Nb2 cells. 
Stationary Nb2 cells were incubated 9 hours with 1: buffer, 2: oPRL lU/ml, 3: mPL-15ng/ml, 4: pGH 1 U/ml, 
5: mPRL 5ng/ml, 6: mPRL 5ng/ml + MRP/PLF 5ng/ml, 7: mPRL 5ng/ml + MRP/PLF 100ng/ml, 8: MRP/PLF 
Sng/ml, 9: MRP/PLF 100ng/ml. DNA synthesis is expressed as fold-over control (cpm with treatment over cpm 
with no treatment) and the error bars indicate the standard deviation from duplicates. 
Chemical deglycosylation of MRP/PLFs with TFMS 
Twenty micrograms of MRP/PLF was added to a mixture containing 5 |ig of each of the 
following proteins: fibronectin, BSA, ovalbumin and cytochrome c. The different proteins 
were added to MRP/PLFs to have a total amount of protein equal to 40 |ig (minimum amount 
of protein recommended for TFMS deglycosylation. The protein mixture containing 
MRP/PLF was treated as described in Materials and Methods. Figure 9 shows that there is no 
detectable accumulation of deglycosylated MRP/PLFs in the reaction mixture. However, 
TFMS treatment leads to the disappearance of MRP/PLFs suggesting that it was degraded 
during the chemical deglycosylation. 
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Figure 9: Chemical deglycosylation of MRP/PLF with TFMS. 
Western blot showing MRP/PLF treated with TFMS or water. 20 p,g of MRP/PLF was combined with 20 |Xg of 
other proteins and treated according to Materials and Methods. The numbers on the left correspond to the 
molecular weight markers described in Materials and Methods. 
DISCUSSION: 
The Nb2 cell bioassay was successfully modified from the previously described assay 
used to detect binding to the prolactin receptor (1, 2). The modifications developed here 
decreased the assay time from 72 h to approximately 15 h. 
Prolactin inhibited DNA synthesis stimulated by MRP/PLFs, in a concentration 
dependent manner, on uterine primary cell cultures. However prolactin does not bind to the 
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MRP/PLF receptor (6). Therefore Prolactin could act through another receptor on the cells that 
are responsive to MRP/PLFs thus acting on a pathway which would inhibit the action of 
MRP/PLFs. Alternatively, prolactin could induce a different cell type also present in primary 
uterine cell cultures to synthesize molecules that will decrease the DNA synthesis of the 
MRP/PLFs stimulated cells. Corroborating evidence could show a role for MRP/PLF 
regulation by prolactin or a lactogenic hormone (most likely placental lactogen I and 11(11)) 
which are secreted during mid-gestation by the placenta. 
The absence of stimulation by MRP/PLFs of the Nb2 cells confirmed the finding that 
MRP/PLFs can not act through the prolactin receptor (7). Furthermore, MRP/PLFs did not 
decrease the activity of mPRL in the Nb2 cell. The high degree of homology between the 
primary protein structures of MRP/PLFs, prolactin and growth hormone suggest that the 
tertiary structures would be similar and MRP/PLFs could bind to the lactogenic receptor like 
the classical members of the prolactin/growth hormone family (12). One hypothesis is that the 
heavy glycosylation of MRP/PLFs would prevent the binding to the lactogenic receptor. The 
difference in glycosylation of prolactin could also explain its inability to bind to the MRP/PLF 
receptor observed in previous experiments (6). 
To identify the roles of glycosylation, deglycosylated MRP/PLF would be required for 
the Nb2 cell bioassay. The chemical method was the most economical and the fastest to 
perform compared to the use of endoglycosidases. Also as time was a factor, site-directed 
mutagenesis or bacterial expression (because a new purification process would have to be 
developed) was not considered as the first option. Unfortunately, the TFMS method degraded 
MRP/PLFs significantly and the incubation time used might not have been long enough to 
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detect the accumulation of deglycosylate MRP/PLFs. At the time, not enough MRP/PLFs was 
available to optimize the chemical deglycosylation to obtain deglycosylated MRP/PLFs. 
In summary, the batch of MRP/PLFs isolated from BN/L cells used in these experiments 
stimulated uterine cell proliferation whereas mPRL did not. Interestingly, mPRL inhibited the 
effect of MRP/PLFs on uterine primary cell cultures. Finally, MRP/PLFs isolated from BN/L 
cells did not activate the prolactin receptor as was reported before for recombinant PLF1 
isolated from CHO cells (7). 
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